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General introduction 
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Introduction to photodynamic therapy 
Photodynamic therapy (PDT) is a treatment modality, which is at present 
widely used on an experimental basis for the treatment of cancer patients. It is 
based on the light induced excitation of light sensitive chemical compounds 
localized in malignant tissue. These so-called photosensitizers are capable of 
absorbing photons due to their extended conjugated ring systems. As a result the 
compound is excited to the singlet state. By decay of the excited electrons to the 
ground state electromagnetic energy is released in the form of fluorescence, but 
some singlet state molecules will undergo intersystem crossover to the triplet state. 
The energy of these triplet state molecules is conveyed in either of two ways. I) In 
the absence of oxygen electrons are transferred to other molecules of the 
photosensitizer or to biological substrates which will lead to negatively or 
positively charged radicals (Type I reaction). 2) In the presence of oxygen the 
energy of the photoexcited sensitizer is directly transferred to oxygen, leading to 
the formation of singlet oxygen (Type IT reaction). As a result of these reactions 
the excited photosensitizer will return to its ground state ready to absorb photons 
again. 
Selectivity and application of PDT 
Over the past decade several photosensitizers have been developed differing in 
physical/chemical properties that determine the cellular localization and intensity 
of the above-described cytotoxic reactions. The first sensitizer to be used clinically 
was hematoporphyrin derivative (HPD). This sensitizer consists of a mixture of 
mono-, di-, and oligomers of hematoporphyrin. Photofrin (PIT) is a refined form of 
HPD enriched in the photoactive moiety. Although widely used in clinical settings, 
both sensitizers have the disadvantage of aselectivity, that is these photosensitizers 
are retained for a long period of time in normal tissue like skin. In search for 
compounds that are more selective for the intended target tissue and show a 
reduced clearance time from normal tissue the so-called second generation 
photosensitizers have been developed. Examples of these second generation 
photosensitizers are phtalocyanines, (bacterio )chlorins, purpurins and benzopor-
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phyrin derivatives. Photochemical activity in target tissue can be achieved in either 
of two ways: I) by systemic administration of the above-described exogenous 
photosensitizers or 2) by the generation of endogenous photosensitizers in target 
tissue. The latter is achieved by the (topical) administration of 5-amino-levulinic-
acid (ALA). This compound has no photochemical activity on its own, but 
bypasses the rate limiting step of haem synthesis leading to an excess of 
endogenous protoporphyrin IX in target tissue, which does have photochemical 
activity. 
After systemic administration the lipophilic photosensitizers tend to bind to 
lipoproteins in the blood. Since fast growing cells like tumor cells need more 
cholesterol then resting cells, photosensitizers accumulate to a higher extent in 
these cells. Therefore PDT in principle can be used for treatment of cancerous 
conditions, under the condition that light can be directed to the treatment site only 
in order to spare the non-malignant tissue. At first PDT was applied as a palliative 
treatment for various cancers. Nowadays PIT-based PDT is registered in various 
countries for treatment of (early stage) cancers of the lung, esophagus, stomach, 
cervix and bladder. Preclinical studies have shown that PDT might be applicable 
for other malignancies as well. In addition to treatment of cancers specific 
photo sensitizers can be used for early diagnosis for malignancies. This is based on 
the above-described preferential accumulation of lipophilic photosensitizers in 
tumor cells and the fluorescence emitted by the photosensitizer upon illumination. 
PDT is also used in non-malignant applications like cosmetic removal of age 
related macular degeneration and for purging donor blood from HIY or other viral 
infected blood cells. Recent and promising applications of PDT concern non-
cancer related diseases like psoriasis, intimal hyperplasialrestenosis, and 
rheumatoid arthritis. 
To activate the photosensitizers present in target tissue local illumination is 
needed. In PDT this is achieved mainly by use of argon pumped dye or diode 
lasers. These devices are capable of producing light of a single wavelength 
matching a specific absorption maximum of the applied photosensitizer. Normally, 
red or infrared light (wavelengths of 610 nm and higher) is used to activate 
photosensitizers. Although absorption by the photosensitizers HPD and PIT is not 
maximal in this region of the visible spectrum light of longer wavelengths 
penetrates deeper in tissue and thus will reach more likely the photosensitizers in 
target tissue. Laser light is usually directed to the target tissue via optical fibers 
and dispersed via light diffusers shaped in a form matching the form of the tissue 
or organ to be treated. Due to recent developments in endoscopic and surgical 
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techniques, virtually every organ or tissue can be reached for treatment. 
Primary effects of PDT 
The generated singlet oxygen has been identified as extremely oxidative (I). 
Due to this strong reactivity its lifetime in biologic systems is short (less then 40 
ns), and therefore singlet oxygen will exert its oxidative potency only in the 
immediate vicinity of the site in which it was formed (2). In this respect it is 
important to consider the physical and chemical properties of the used 
photosensitizers, since these properties determine the cellular site of oxidation. 
Lipophilic photosensitizers are incorporated in lipid(bi)layers as found in the cell 
membrane, mitochondria, and the nucleus. The PDT-induced singlet oxygen-
mediated oxidation of the cell membrane leads to leakage of electrolytes, 
membrane depolarization, inhibition of uptake of nutrients, and alterations of 
(membrane associated) proteins and enzymes. A visual sign of oxidative damage to 
mitochondrial membranes is the formation of swollen mitochondria. This results in 
the inhibition of the enzymes present in the mitochondrial membrane participating 
in the oxidative phosphorylation and respiratory chain. Consequently, the 
generation of for example ATP is diminished (3). Furthermore, an enhanced 
expression of heat shock proteins (4) and early response genes (5) have been 
observed. Oxidation and disruption of the nuclear envelope exposes the genomic 
DNA to oxidative molecules. Consequently, random DNA single strand breaks can 
occur and DNA-DNA and DNA-protein cross-links may be induced. In contrast to 
lipophilic photosensitizers, hydrophilic photosensitizers are preferentially 
accumulated into lysosomes and endosomes after pino- or endocytosis. As a 
consequence mainly these organelles are disrupted upon illumination. This leads to 
the release of protein degrading enzymes into the cytoplasm resulting in necrotic 
cell death (6). 
Recent studies have focussed on the phenomenon of programmed cell death or 
apoptosis of various types of tumor cells as a resnlt of the application of PDT. 
Soon after PDT the cell membrane folds into small buds which eventually pinch 
off from the cell surface. This so-called blebbing of the cell is considered to be one 
of the symptoms associated with apoptosis. Another symptom is DNA 
fragmentation, which is apparent within hours after the start of illumination of 
various photosensitizers like aluminium phthalocyanine (7), photofrin (Pil), both 
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in vitro (8) and in vivo (9), and 5-aminolaevulinic acid (10). The important role of 
serine/threonine and tyrosine protein kinases and phosphatases in the signal 
transduction pathways leading to the activation of DNA-se under PDT, have been 
outlined recently (11,12). Activated DNA-se can split DNA at sites unprotected by 
nucleosomes, thereby generating strands of discrete length (the so-called 
laddering). On the other hand, Dougherty et al. (13) proposed that PDT might 
initiate direct apoptotic responses, like the afore-mentioned DNA laddering, 
without the need for intermediate signal transduction pathways that may be 
missing in certain neoplastic cells. Nevertheless, the study on how exactly PDT 
activates signal transduction routes (involvement of cytochromes, caspases) 
leading eventually to apoptosis of the cell is continued. 
Secondary effects of PDT 
(1) Vascular damage 
Depending on the photosensitizer not only tumor cells are directly affected by 
PDT but also the endothelial cells of the tumor vasculature which are the most 
proximate cells to the blood circulation. Endothelial cells are extremely sensitive 
to PDT (14,15). Direct cytotoxicity as a result of uptake and illumination of 
photosensitizers causes the retraction of endothelial cells (16). Subsequently, 
blood plasma and proteins will leak into the treated tissue causing the (temporary) 
swelling of the tumor. The exposed subendothelial matrix is highly thrombogenic. 
Upon their adherence thrombocytes are activated and release potent vasoactive 
eicosanoids like thromboxane (17). This leads to a (temporary) constriction of 
primarily arterioles (18). In the presence of clotting factors released by endothelial 
cells upon PDT (19), thrombi are formed that occlude the blood vessels. Both the 
occlusion and constriction of blood vessels eventually lead to a complete stasis of 
the blood flow. It was postulated that this secondary effect of PDT could 
contribute to indirect tumor cell kill by the deprivation of oxygen and nutrients 
(20). Indeed, it was found that the clonogenicity of tumor cells is not directly 
affected after in vivo PIT-based PDT, but deteriorates with the gradual reduction in 
oxygen and nutrients supply in time (21). The necessity of vascular damage for 
tumor regression seems further supported by the fact that indomethacine (22) or 
indomethacine-related drugs (23) and aspirin (24,25), which all inhibit the release 
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of thromboxane by activated thrombocytes, decreased the efficacy of PDT and the 
vascular responses after PDT. Nowadays it is widely accepted that the damaging 
effect of PDT on the tumor vasculature is indispensable for tumor cell death. 
Secondary effects of PDT 
(2) Activation of the immune system 
Photooxidation of the lipids and proteins of plasma membranes of tumor cells 
also induces the rapid activation of membrane-borne phospholipases (26). This 
results not only in the accelerated degradation of oxidized phospholipids but also 
induces a massive release of I ipid fragments and metabolites of arachidonic acid 
(27). These substances are highly chemotactic, enabling a massive recruitment of 
immune cells to the damaged site. Other humoral immunological mediators like 
histamine, components of the complement cascade, and proteins of the clotting 
system have been implicated in the PDT-induced accumulation of immune cells 
(28). 
Cytokines are important messenger proteins, regulating the inflammatory and 
immunological responses of the host towards invading bacteria, viruses and so on. 
Interleukin-I (IL-I), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-a) are 
so-called pro-inflammatory cytokines, that is they are capable of inducing or 
enhancing an inflammatory response directed to the tumor site. 111 vitro IL-6 
expression was induced at both the mRNA and protein level of Hela epithelial 
cells (29) and murine macrophages expressed TNF-a upon stimulation by PDT 
(30). PDT can affect the expression of IL-6 and IL-IO of tumor and normal tissues 
il1 vivo (31). In the urine of patients undergoing PDT of the bladder enhanced 
levels of IL-l~, IL-2, and TNF-a were found as compared to healthy control 
subjects (32) Apparently, PDT is capable of inducing the expression or enhancing 
the levels of several cytokines. 
Induction of cellular responses after PDT has been documented as well. Within 
5 min after the start of PIT-based PDT of rat cremaster muscle adhesion of 
granulocytes to the vessel wall has been observed (17). In murine squamous 
carcinoma tumors this is followed by a rapid and massive accumulation of 
neutrophils after the start of PIT-based PDT (33). It is likely that these phagocytes 
are present at the inflammatory site to remove tumor cell debris caused by PDT. 
Whether this is the only role of neutrophils in the PDT-induced tumor cell death 
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remains unknown. Later, other immune effector cells like lymphocytes and 
monocytes/macrophages are recruited to the lesion. The latter cells are tumoricidal 
by themselves. Both in vitro (34) and in vivo (33,35) experiments have shown that 
PDT can potentiate this function. 
Macrophages were reported to preferentially recognize PDT treated cancer 
cells as their targets (36). After phagocytosis and processing of tumor cell debris 
these macrophages function as so-called antigenpresentingcells (APCs). Upon 
presentation of tumor associated proteins in the context of MHC II molecules on 
the membranes of APCs, CD4+ T-lymphocytes may recognize the antigens, 
become activated and start to proliferate. These lymphocytes in turn will enhance 
the proliferation of activated CD8+ T-lymphocytes. This is of course a desirable 
situation since systemic immunity may lead to the eradication of untreated tumors 
as well. Severe combined immunodeficient (SCID) or nude mice showed no 
complete cure from sarcoma tumors by PDT alone. However, after the 
transplantation of bone marrow from immunocompetent BALB/c mice cured by 
PDT a complete remission occurred after PDT (37). This was also the case when 
spleen cells from BALB/c mice cured from sarcoma tumors were adoptively 
transferred to SCID mice (27). Spleen cells from BALB/C mice cured from other 
tumors or virgin spleen cells did not have that ability. These experiments suggest 
the involvement of memory (T) cells sensitized to the tumor treated by PDT. 
Evidence for the involvement of other specific immune cells like B-lymphocytes or 
natural killer cells is still scantly at the moment. 
On the basis of the acquired knowledge about the mechanisms underlying the 
indirect cell kill of PDT the question was studied if the efficacy of PDT could be 
improved by enhancing the tumor directed immune response. These studies 
include the stimulation of the non-specific immune response after 
hematoporphyrin derivative-sensitized-phototherapy of murine transitional cell 
carcinomas by injection of Corynebacterium parvUl11 (38), or Bacillus Calmette-
Guerin (39). Mycobacterium cell-wall extract was used to increase the curative 
effect of PDT on murine EMT6 tumors (40), and the non-specific 
immunostimulator schizophyllan to improve the PDT treatment of squamous cell 
carcinomas (41). 
All these strategies appear to improve the efficacy of PDT, but do have the 
disadvantage of being not specific. A more specific approach to potentiate the 
effect of PDT was directed to the activation of tumoricidal macrophages. This was 
achieved by the administration of granulocyte-macrophage colony-stimulating 
factor (GM-CSF; 42). This growth factor is a key regulator controlling maturation 
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and function of both granulocytes and monocytes/macrophages. Macrophages can 
also be activated by a specific macrophage-activating factor derived from vitamin 
OJ-binding protein. The systemic injection of this protein potentiated the curative 
effect of PDT on murine squamous cell carcinoma (43). Reports on cytokine use to 
stimulate the inflammatory reaction induced by PDT are scarce. So far only the 
administration of the pro-inflammatory recombinant human TNF-a has been 
reported to stimulate PDT (44). 
Aim of this study 
The finding that PDT evokes an inflammatory reaction JD the tumor lesion 
provides the opportunity to increase the potency of this treatment modality by 
modulating the inflammatory response. In the past, this was achieved by 
stimulating the overall immune reaction by heat-killed bacteria or bacterial 
products, which indeed successfully enhanced the tumor cure rates of PDT. 
Obviously, tumor associated macrophages are the chief and final executioners of 
tumor cell death under those conditions. The significance of the observed adhesion 
of granulocytes and the consequences of this phenomenon for the efficacy of PDT 
however are less clear. The aim of this study was therefore to elucidate the 
mechanisms underlying the interaction between endothelial cells and granulocytes 
and to investigate the relevance of this interaction for the effect of PDT. This may 
lead to new ways for a specific stimulation of the potency of PDT. 
Outline of this thesis 
Chapter 2 describes the in vitro model used to study the interaction of 
endothelial cells and granulocytes. In this model, human umbilical vein endothelial 
cells grown to confIuency on plastic culture dishes were treated by PDT before 
incubation with freshly isolated human granulocytes. The adhesion of granulocytes 
was studied both quantitatively and qualitatively. The contribution of various 
cellular adhesion molecules on both the endothelium and granulocytes to the 
observed adhesion was determined using inhibitive compounds. Furthermore, we 
questioned whether the activation status of the granulocytes used was altered and 
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was of relevance to the adhesion. 
In chapter 3 the findings of the PDT-induced interaction of endothelial cells 
and granulocytes are extended in the context of the suitability of PDT to prevent 
restenosis after coronary angioplasty. In this chapter we studied if a decrease in the 
anti-adhesive ability of PDT treated endothelial cells underlied the increased 
adherence of neutrophils. To this end we determined the release of the anti-
adhesive factors nitric oxide and prostacyclin. Furthermore, the expression of the 
neutrophil adhesion molecule P-selectin on endothelial cells and the release of the 
neutrophil adhesive protein von Willebrand factor by endothelial cells upon PDT 
treatment was investigated. 
In chapter 4 the therapeutic significance of the granulocyte adherence after 
PDT was studied in an in vivo model using rats transplanted with 
rhabdomyosarcoma tumors. To this end two approaches were used: I) a decrease 
in the number of circulating neutrophils in the blood of the tumor-bearing rats 
prior to PDT by the administration of anti-granulocyte antiserum, and 2) an 
increase of the number of circulating granulocytes prior PDT by the administration 
of granulocyte-colony stimulating factor (G-CSF). The effect of these adjunctive 
treatments on the tumor growth is described. 
Chapter 5 extends the investigations in the in vivo model. It was observed that 
very early after the start of PDT granulocytosis occured. The mechanism 
underlying this increase in the number of granulocytes was studied by determining 
the time courses of the levels of the pro-inflammatory cytokines IL-113 and TNF-a 
in the circulation. Furthermore the role of G-CSF in the granulocytosis and tumor 
growth was investigated by the use of anti-G-CSF monoclonal antibodies. 
Chapter 6 deals with the significance of the vascular response after PDT. Blood 
flow stasis appears indispensable for indirect tumor cell death upon PIT-based 
PDT, since direct cell kill by the generation of singlet oxygen is limited because of 
the transient vessel constriction. In order to leave the blood vessels open during 
PDT, rats transplanted with rhabdomyosarcoma tumors were treated with anti 
thrombocyte antiserum prior or post PDT. The effect of this treatment on tumor 
response at two illumination protocols and the possible mechanism are described. 
In chapter 7 the results of the present studies are summarized and discussed in 
the context of current concepts in the literature. 
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CHAPTER 2 
Photodynamic treatment of human endothelial cells 
promotes the adherence of neutrophils in vitro 
Wil J.A. de Vree, AmeliaN.R.D. Fontijne-Dorsman, 
Johan F. Koster, and Wim Sluiter. 
(British Journal of Cancer 73: 1335-1340, 1996) 
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Abstract 
The effects of photodynamic treatment (PDT) on venules include vascular 
leakage accompanied by edema formation, vasoconstriction and blood flow stasis. 
The goal of this study was to gain insight into the mechanism underlying these 
vascular events by studying one of the earliest observations after PDT, that is 
granulocyte adhesion, in an in vitro model. 
For this purpose human umbilical vein endothelial cells (HUVEC) preincubated 
with Photofrin II (PIl) were illuminated with red light and incubated with 
neutrophils. PDT led to a dramatic change in the morphology of the endothelial cells. 
Clearly, neutrophils adhered to the subendothelial matrix and their adherence 
coincided with an increase in the percentage of exposed subendothelial matrix by the 
gradual contraction of endothelial cells. Furthermore, the increase in adherence was 
dependent on dmg dose, illumination time and the time delay after PDT. 
The neutrophil adherence could be inhibited by anti-~2 integrin antibodies, which 
suggests that the UL-, UM- or UX-~2 receptors of the neutrophil mediated this 
phenomenon. At 4°C or by preincubation of the neutrophils with staurosporin their 
adherence to the subendothelial matrix exposed by PDT of endothelial cells could be 
prevented. Apparently, activation of the ~2-integrin receptor by interaction with the 
subendothelial matrix is necessary for the increased binding of neutrophils. 
Taken together, these in. vitro findings suggest that the PDT -induced contraction 
of the endothelial cells permits neutrophil adherence to the subendothelial matrix. It 
is conceivable that a similar mechanism contributes to the initial adherence of 
granulocytes to the vessel wall as observed after PDT in vivo. 
Introduction 
Photodynamic treatment is a relative new therapy for the treatment of various 
forms of cancer (I). The therapy involves the systemic administration of a 
photosensitizer followed, after some hours to days necessary for the relative 
accumulation of the sensitizer in the tumor, by the illumination of the tumor area 
with light of appropriate wavelength. At present Photofrin rr" (pm, a mixture of 
haematoporphyrins is the only photosensitizer used with limited approval for use in 
cancer patients. Its illumination leads to the formation of highly reactive oxygen 
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species such as singlet oxygen (2,3). Singlet oxygen is involved in direct cell 
cytotoxicity by oxidation of the plasma membranes, mitochondria and Iysosomes 
(4,5). 
Besides this direct cell kill, PDT also is reported to mediate vasoconstriction and 
blood flow stasis (6). These events appear to be indispensable in the destruction of 
tumor tissue (7,S). One of the earliest events after PDT observed in rat cremaster 
muscle vessels (9) and rat skinfold vessels (own unpublished observation) is the 
adhesion of granulocytes to the vessel wall. Granulocytes play a key role in 
inflammatory reactions and these phagocytes therefore may also contribute to tumor 
destruction after PDT. Although the effect of PDT on endothelium has been the 
subject of many studies (10-14) the mechanism underlying the adherence of 
granulocytes to the endothelial lining is not known. 
In this study we investigated in an ill vitro model the adherence of neutrophils 
after PDT of endothelial cells in order to elucidate this phenomenon. 
Materials and methods 
Photosensitizer and drugs 
The photosensitizer Photofrin II" (PI!) was obtained from Quadra Logic 
Technologies Inc. (Vancouver, BC, Canada) and was reconstituted in 5% glucose 
before use. Mepacrine was from Sigma Chemical Co. (St. Louis, MO, USA). WEB 
20S6 was kindly provided by Boehringer Ingelheim (Ingelheim, Germany). 
Monoclonal antibodies (MAb) 
MAb to the ~J- (CD29), ~2- (CDlS), and ~3- (CD 61) integrins and a mouse 
control IgGJ MAb were purchased from Becton-Dickinson (San Jose, CA, USA). 
Isolation and culture of endothelial cells 
Endothelial cells were isolated and cultured according to previously described 
methods (15) with minor adaptations. In short, the cells were isolated from umbilical 
cords which were kept in cord buffer (140 mM NaC!, 4 mM KCI, II mM D-glucose, 
10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; pH 7.3). A vein was 
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cannulated and rinsed with cord buffer before endothelial cells were detached by 20 
min incubation at 37°C in 0.1 % collagenase (Sigma Chemical Co., St. Louis, MO, 
USA) in MI99 medium (Flow Laboratories, Irvine, Scotland). Cells were collected 
by perfusion with MI99 and centrifugation (400 x g, 10 min) and next resuspended 
in culture medium: MI99 medium supplemented with 10% pooled human serum 
(Red Cross Bloodbank, Rotterdam, The Netherlands), 10% fetal calf serum 
(Boehringer Mannheim, Mannheim, Germany), 175 J.Lg/m! endothelial cell growth 
factor isolated as previously described (16), 840 J.Lg/m! NaHCOJ, 15 Ulm! heparin 
(Leo Pharmaceutical Products, Weesp, The Netherlands) and 50 U/m! penicillin and 
50 J.Lg/m! streptomycin (Boehringer Mannheim, Mannheim, Germany) in 25 cm' 
culture flasks precoated for 30 min at room temperature with 10 J.Lg/m! fibronectin 
isolated as previously described (17). Endothelial cells were identified by well-
accepted methods (15). When grown to confluence the cells were detached with 
trypsinlEDTA (Gibco, Breda, The Netherlands) and subcultured in fibronectin-
precoated 96- or 24-wells culture plates or were stored in liquid nitrogen until use. 
For experiments, only confluent monolayers between passage I to 6 at least three 
days after subculture were used. 
Isolation of neutrophils 
Neutrophils were isolated from fresh citrated human blood (kindly provided by 
the Red Cross Bloodbank, Rotterdam, The Netherlands). In short, blood cells were 
diluted two times in PBS and separated by density gradient centrifugation (800 x g, 
20 min at room temperature) over isotonic Lymphoprep (9.6% sodium metrizoate 
and 5.6% Ficoll; density 1.077 g/ml; Nycomed, Oslo, Norway). The pellet fraction, 
containing erythrocytes and granulocytes was treated twice with ice-cold isotonic 
ammonium-solution (155 ruM NH4CI, 10 mM NaHC03 and 0.1 ruM EDTA) to lyse 
the erythrocytes. The remaining granulocytes were washed with PBS and 
resuspended in PBS. In general this fraction contained approximately 95 to 100% 
granulocytes, of which the majority (94%) were neutrophils. 
PDT protocol 
Endothelial cells in 24- or 96-wells culture plates were incubated with PIT at a 
concentration of 25 J.Lg/ml (unless stated otherwise) in culture medium for 20 h at 
37°C, 5% CO, and 100% humidity. This concentration equals the initial plasma level 
of PIT in patients after injection of 2 mg/kg. Next, cells were washed three times and 
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suspended in Krebs-Ringer bicarbonate buffer (118 mM NaC!, 4.7 mM KCI, 1.0 mM 
CaCb, 1.2 mM KH,P04, 1.2 mM MgS04.7H20, 25 mM NaHC03, 10 mM N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid, and 5.5 mM glucose; pH 7.3). For 
light treatment culture plates were illuminated in a mirror box for 15 min (unless 
stated otherwise). Red light was delivered by a slide projector with a 250-W lamp 
(type 7748S EHJ, Philips, Eindhoven, The Netherlands) and a cut-off filter « 610 
nm, #59512, Oriel Co., Stratford, CT, USA). Average fluence rate was measured in 
the culture wells with an isotropic light detector and amounted to 4 m W/cm', which 
leads to 3.6 J/cm2 after 15 min of illumination. After illumination the endothelial 
cells were incubated at 37°C, 5% C02 and 100% humidity for 30 min (unless stated 
otherwise) and then freshly isolated neutrophils were added. After 10 min of 
incubation (unless stated otherwise) the culture plates were washed three times with 
ice-cold PBS to remove the non-adherent cells. 
Determination of neutrophil adherence 
Myelo-peroxidase (MPO) was used as au enzymatic marker to quantify the 
number of adherent neutrophils according to previously described methods (18). 
Briefly, the adherent neutrophils were lysed during 15 min at 4°C with 0.5% 
hexadecyltrimethylammonium-bromide (HTAB) in PBS (pH 6.0). The amount of 
MPO activity in the lysate, which reflects the number of adherent neutrophils was 
determined by a colorimetric assay using o-dianisidine dihydrochloride (0.2 mg/ml) 
and H202 (2 mM) in PBS (pH 6.0). The change in absorbance at 450 nm was 
followed during 15 min at 37°C in a Thermomax microplate reader (Sopar Biochem, 
Nieuwegein, The Netherlands). The number of adherent neutrophils was determined 
from the maximal velocity by interpolating from a standard concentration curve and 
the adherence expressed as the percentage of the total number of added neutrophils. 
Determination of lactate dehydrogenase (LDH) 
Homogenates of HUVEC were obtained by sonification during 5 min on ice of 
the endothelial monolayer in phosphate buffer (100 mM KH2P04 and 100 mM 
Na2HP04; pH 7.0). In both homogenates and culture supernatants LDH-activity was 
determined by a colorimetric assay with pyruvate (5.75 mg/ml) and NADH (4.7 
mg/ml) as substrates. Absorbance was read at 340 nm with a Thermomax microplate 
reader. 
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Measurements of porphyrin levels 
Porphyrin levels in endothelial cells were determined as previously described for 
animal tissues (6). Endothelial cells were lysed with 0.1 M NaOH. Porphyrins in the 
lysate were hydrolysed and extracted by adding 2% sodium dodecyl sulphate (SDS) 
followed by heating (100°C) during IS min. After centrifugation (1500 x g, IS min) 
fluorescence intensity in the supernatant was measured in a fluorescence 
spectrophotometer (MPF-3, Perkin Elmer Corporation, Norwalk, CN, USA) at an 
excitation wavelength of 404 nm and an emission wavelength of 627 nm. 
Fluorescence peaks were compared with standards of known concentrations of PIT in 
2% SDS and 0.1 M NaOH to calculate the amount of porphyrins retained in the 
endothelial cells. 
Determination of the exposed surface area 
To determine the size of the exposed area of the subendothelial matrix time-lapse 
pictures after PDT of the endothelium were analyzed by measuring the surface area 
of the endothelial cells in relation to the total area. This was performed with the 
software-drafting package Autosketch 2.0 obtained from Autodesk Inc. (Sausalito, 
CA, USA). 
Statistical Analysis 
Data are presented as means ± s.d. of triplicate experiments (unless otherwise 
stated) and were analysed using multiple regression analysis, Student's t -test or 
analysis of variance (ANOVA) with Bonferroni's cOlTection where appropriate. 
Differences between group-means were considered significant when P<0.05. 
Results 
Effect of PDT of endothelial cells on the adhesion of neutrophils 
To elucidate the mechanism underlying the increased adherence of granulocytes 
after PDT we investigated the effect of PDT of endothelial cells on the adherence of 
blood neutrophils in vitro. For this purpose neutrophils were added for 10 min at 
24 
various time-delays after illumination (15 min of red light) of PIT-treated (25 Ilglml 
for 20 h) HUVEC. The results show that the adherence of neutrophils increased 
linearly (R2=0.850, P<O.OOOI) with time to a maximum at a time delay of 30 min 
before neutrophil addition and then remained at that increased level up to the end of 
the observation period (Figure 1). Pretreatment of endothelial cells with PIT or light 
only had no significant effect on the adherence of neutrophils as compared to 
untreated HUVEC. 
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Figure I. Relationship between the adherence of neutrophils and the time delay of their 
addition after PDT of HUVEC. After their addition neutrophils were allowed to 
adhere for 10 min. Next, non-adherent cells were removed. The adherence is 
expressed as the percentage bound neutrophils corrected for the adherence after 
treatment of HUVEC by red light only. The data represent the mean ± s.d. of three 
separate experiments with determinations in triplicate. 
To study if this increased adherence was drug dose-dependent, HUVEC were 
pre incubated with various concentrations of PIT for 20 h and thereafter illuminated 
for 15 min. Neutrophils were added after a time delay of 30 min, which is sufficient 
for maximal adherence (cf. Figure 1). As shown in Figure 2 there was a linear 
relationship between PIT-dose and neutrophil adhesion (R'=0.962, P<O.OOOl). To 
investigate whether this drug dose-dependent effect of PDT on the neutrophil 
adherence was directly associated with the amount of PIT in HUVEC the porphyrin 
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concentration retained after 20 h of PIT incubation in serum-supplemented Ml99 was 
determined (Figure 2). A linear relationship between the incubation dose and the 
cellular porphyrin content was found (R2=0.94, P<O.OOOl). Approximately 0.3 to 
0.6% percent of the amount of administered PIT was retained by the cells. 
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Figure 2. Relationship between the amount of PI! in the endothelial culture medium 
(abscissa), the amount of PI! retained by the endothelial cells (closed circle; right 
ordinate) and the adherence of neutrophils after PDT of the endothelium (open 
circle; left ordinate). The adherence of neutrophils was corrected for the 
adherence after treatment of HUVEC by red light only. The data represent the 
mean ± s.d. of three separate experiments with determinations in triplicate. 
To evaluate if the effect of PDT was dependent on the light-energy dose 
HUVEC were illuminated for various times after treatment for 20 h with a fixed 
dose of PH (25 Itg/ml). Neutrophils were added after a delay of 30 min after the 
end of illumination. Upto 20 min of illumination, which is equivalent to 4.8 J/em2, 
we found a linear relationship between the illumination time and the adherence of 
neutrophils (Figure 3; R2=0.662, P<O.OOOI). The adherence reached a maximum at 
20 min of illumination. Longer illumination times did not lead to further increment 
of neutrophil adherence. 
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Figure 3. Relationship between the adherence of neutrophils and the red light dose 
(illumination time) used for PDT of HUVEC. After various periods of 
illumination the neutrophils were added 30 min later and allowed to adhere for 
10 min. The adherence of neutrophils was corrected for the adherence after 
treatment of HUVEC by red light only. The data represent the mean ± SD of 
three separate experiments with determinations in triplicate. 
Mechanism of adhesion 
Light microscopic study of the endothelial cells at 30 min after PDT (cf. Figure 1) 
showed that the morphology of the endothelial cell was dramatically altered as 
compared to control HUVEC (Figure 4a,b). Retraction of the endothelial cells and 
formation of large membrane vesicles was observed resulting in the exposure of a 
large area of the subendothelial matrix. The adherent neutrophils were mainly 
associated with this exposed matrix rather than the contracted endothelial cells 
(Figure 4c). To examine whether a decrease in membrane integrity of HUVEC 
occurred after this PDT protocol, the release of LDH was determined 30 min post 
PDT (Table 1). We found no significant increase in LDH-release which indicates 
that the membrane integrity of the endothelial cells was not severly affected at that 
time. 
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Figure 4. Effect of PDT on the morpho-
logy of endothelial cells and the adherence 
of neutrophils. Endothelial cells were 
photographed at 30 min after red light 
treatment only (A) or 30 min afler PDT 
(B) or 30 min afler PDT followed by 
addition of neutrophils for 10 min (C). 
Note the presence of large membrane 
vesicles (open arrow) and "pseudopodia" 
(closed anow) afler PDT of HUVEC. 
Magnification A,B,C: x 200. 
Table I. Effect of photodynamic treatment (PDT) of human umbilical vein endothelial cells 
(HUVEC) on the release of lactate dehydrogenase (LDH). 
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Condition % LDH in % LDH in 
HUVEC supernatant 
Untreated 91.8 ± 2.7 8.2 ± 2.7 
PI! only 89.3 ±4.5 10.7 ±4.5 
Red light only 88.0±4.8 12.0 ± 4.8 
PDT 85.1±7.1 14.9±7.1 
Data are the means ± SD of three experiments. The percentage of LDH was 
calculated from the total amount in supernatant and cells. Measurements were 
performed in triplicate. 
To determine whether the extent of exposure of the subendothelial matrix was 
related to the increased adherence of neutrophils pictures were taken at various time 
delays after PDT to measure the exposed matrix. As shown in Figure 5 there was an 
increase in the percentage exposed area from 20% at 10 min to approximately 65% at 
40 min after PDT. 
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Figure 5. Time course of exposure of the subendothelial matrix after PDT of HUVEC. The 
percentage exposed surface was determined as described under material and 
methods. 
To study whether the adhesiveness of the matrix for neutrophils was dependent 
on a direct effect of PDT, the contraction of the endothelial cells was induced by 
calcium-free buffer (PBS) instead of PDT. The results show that the increase in 
neutrophil adherence to this matrix was similar in magnitude as to the matrix 
exposed by PDT-induced contraction of the endothelial cells (Figure 6), showing that 
the adhesiveness of the subendothelial matrix per se does not depend on PDT. 
Furthermore, we found that PDT of fibronectin, which we used to coat the 
endothelial culture wells, did not lead to an increase in its adhesive properties for 
neutrophils (Figure 6). To investigate which type of membrane receptor is involved 
in the increased adherence neutrophils were preincubated for 30 min with blocking 
MAb to members of the ~I'- ~2- or ~3-integrin adhesion receptor family (Figure 7). 
Preincubation with anti-~I (CD29) or anti-~3 (CD61) MAb did not influence 
neutrophil adherence as compared to control MAb. However, incubation of 
neutrophils with Mab to ~2-integrin (CDl8) blocked their adherence substantially. 
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Figure 6. Adherence of neutrophils to the subendothelial matrix. Neutrophils were added 
after red light only (dark-grey bar) or PDT (light-grey bar) treatment of fibronectin 
(FIBRO) or endothelial monolayer (HUVEC) or treatment of the monolayer with 
calcium-free PBS (black bar). Each bar represents the mean ± SD of three 
detenninations. 
anti-Bl 
anti-B2 
anti-B3 
mIgG 
o 10 20 30 40 
ADHERENCE OF NEUTROPHILS (%) 
Figure 7. Effect of monoclonal antibodies (MAb) to isotypes of the integrin receptor on the 
adherence of neutrophils after PDT of HUVEC. Neutrophils were preincubated for 
30 min at 4"C with 10 Ilglrnl of the MAb under investigation and then added to 
HUVEC 30 min post PDT for 10 min at 37"C in the presence of that MAb. Each 
bar represents the mean ± SD of three determinations. 
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Since it is known that efficient binding of a leucocyte to its ligand depends on a 
protein kinase C-dependent phosphorylation of the ~2-receptor (19), we studied 
whether intracellular signaling via protein kinases was involved in the increased 
adherence of neutrophils under the present conditions as well. We found that at 4°C 
neutrophils failed to adhere (0% ± 0%, not shown). Furthermore, preincubation of 
neutrophils with staurosporin, a protein kinase inhibitor, prevented their adherence in 
a concentration-dependent fashion (Figure 8). At the highest concentration of 
staurosporin, which almost completely prevented the neutrophil adherence, the 
viability of neutrophils during the experiment was not affected as monitored by 
trypan blue exclusion. 
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Figure 8. Effect of staurosporin on the adherence of neutrophils. Neutrophils were 
preincubated for 10 min at 4°C with various concentrations of staurosporin (closed 
circle) or solvent (DMSO) only (open circle) and then added to HUVEC 30 min 
post PDT for 10 min at 37'C in the presence of staurosporin or DMSO. The data 
represent the mean ± SD of three determinations. 
Discussion 
The major finding of this study was that PDT of endothelial cells in vitro led to an 
increased adherence of neutrophils to the subendothelial matrix. This adherence was 
dependent on the PIT dose, the illumination time and timecourse after PDT. The 
gradual increase in neutrophil adherence coincided with a gradual exposure of the 
subendothelial matrix (ECM) due to contraction of the endothelial cells. 
31 
The endothelium after PDT showed a striking resemblance with the morphology 
of endothelial cells treated by tert-butylhydroperoxide (t-BuOOH), a lipophilic 
reactive oxygen species, namely extensively contracted cells with large membrane 
vesicles (20). Patel et al. (20) showed that the vesicles eventually pinched off and 
contained PAP-like molecules that stimulated the adherence of granulocytes to 
gelatin. PIT is a photosensitizer which is also lipophilic and therefore accumulates in 
the cell membrane. As a result of illumination of the photosensitizer highly reactive 
oxygen species are formed. These may generate PAP or PAF-Iike molecules that 
could be responsible for the increased adherence of neutrophils to the exposed 
subendothelial matrix. However, we found that preincubation of neutrophils for 10 
min with 10-4 to 10-8 M WEB 2086, a synthetic PAP antagonist, did not inhibit their 
adherence 30 min after PDT of HUVEC (not shown). Preincubation of HUVEC for 
10 min with 10-5 to 10-8 M mepacrine, a phospholipase A2 inhibitor that prevents the 
synthesis of PAP, did not inhibit neutrophil adherence either (not shown). This 
indicates that the adherence of neutrophils under the present conditions was not 
mediated by membrane-bound PAP or PAP-like molecules. 
The use of blocking antibodies to three isotypes of the integrin family of adhesion 
receptors show that ~2-integrins on the neutrophil membrane are involved in their 
adherence. Others have shown that a PKC-dependent phosphorylation of the 
cytoplasmic domain of the ~2-integrin receptors of leukocytes is necessary for 
binding to their ligands (J 9). We found that at 4°C and after preincubation of the 
neutrophils with staurosporin the adherence to the exposed subendothelial matrix 
was reduced. This indicates that a protein kinase-dependent activation of the ~2-
receptor is also necessary for binding of neutrophils to the subendothelial matrix 
exposed as a result of PDT of endothelial cells. In vivo also, granulocytes were found 
to adhere to spaces between the endothelial cells after PDT of rat cremaster muscle 
vessels (9). Whether activated ~2-integrins are involved here as well, remains to be 
established. 
The ECM produced by endothelial cells in culture at the baso-Iateral side consists 
of various matrix proteins like collagens (types I, III and IV), proteoglycans (mostly 
heparan and dermatan sulphate proteoglycans), laminin, fibronectin, and elastin. 
Several of these ECM-proteins have been shown to be involved in the adherence of 
neutrophils (21). Which type of ECM-protein is involved here is not known as yet. 
Taken together, we found evidence as to the mechanism of the increased 
adherence of neutrophils after PDT of endothelial cells. Upon this treatment 
endothelial cells contract exposing the ECM. Neutrophils adhere to the ECM by their 
~2-integrin receptors which possibly become activated. It is conceivable that the 
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contraction of endothelial cells induced by PDT contributes to the granulocyte 
adherence as found il1 vivo as well. Whether those phagocytes playa role in further 
vascular collapse and tumour regression after PDT remains to be established. 
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CHAPTER 3 
Prevention of late lumen loss after coronary angioplasty 
by photodynamic therapy: Role of activated neutrophils 
Wim Sluiter, Wil 1.A. de Vree, Anneke Pietersma, and lohan F. Koster. 
(Molecular and Cellular Biochemistry 157: 233-238, 1996) 
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Abstract 
Restenosis after coronary angioplasty arises from fibrocellular intimal hyperplasia 
and possibly failure of the artery to enlarge adequately. Which mechanisms underlie 
this process is only partly understood. No drugs have been clinically effective in 
reducing the incidence of restenosis. Since recently, photodynamic therapy (PDT) is 
being investigated as a possible treatment for intimal hyperplasia. PDT involves the 
systemic administration of a light-excitable photosensitizer that is accumulated at a 
high rate by rapidly proliferating cells. During laser irradiation light energy is 
transferred from the photosensitizer to oxygen generating the highly reactive singlet 
oxygen. This potent oxidizer can cause severe cellular damage. After PDT of a 
balloon-injured artery from the rat and rabbit the media remained acellular for 
several weeks to months, and intimal hyperplasia did not occur. The endothelial 
lining regenerated by two weeks, but why smooth muscle cells did not repopulated 
the media is not known. 
Neutrophils seem to play an important role in the prevention of restenosis after 
coronary angioplasty, since the activation status of this type of phagocyte is directly 
related to vessel diameter at late follow-up. Furthermore, it has been observed that 
neutrophils adhere to the microvascular wall upon PDT in vivo. In vitro findings 
suggest that the increased neutrophil adherence was not dependent on a decreased 
release of the anti-adhesive factors NO and prostacyclin by the PDT-treated 
endothelial cells. Furthermore, PDT did not stimulate the expression of P-selectin by 
the endothelial cells, one of the adhesion receptors for neutrophils. The endothelial 
cells only retract upon PDT allowing the adherence of neutrophils by their ~2-
integrin adhesion receptors to the subendothelial matrix. On the basis of these 
findings, we presume that the successful prevention of intimal hyperplasia by PDT 
partly depends on the presence of the neutrophil at the site of the lesion. 
Introduction 
Percutaneous transluminal coronary angioplasty (PTCA) was first applied 
clinically in the late 1970s by Gruentzig (I) to alleviate the symptoms of coronary 
atherosclerosis. This technique has developed into a major therapeutic tool in the 
treatment of single and multiple vessel coronary artery disease. PTCA involves the 
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placement and inflation of a balloon within a very localized segment of a coronary 
artery. Because PTCA is always performed in the presence of pre-existing disease, 
successful recanalization of the obstructed vessel is accompanied by plaque fissure, 
and frequently results in longitudinal intimal tears and tangential splitting of the 
tunica media (2). 
This form of vascular injury is followed by a healing process that is characterized 
by intimal and medial remodelling, endothelial cell regrowth, medial and intimal cell 
proliferation and increased synthesis of extracellular matrix (2,3). Excessive response 
results in recurrent stenosis that compromised this treatment modality in about 30% 
of the cases (4). This has prompted a large array of new devices to improve final 
outcome, e.g., atherectomy devices, laser angioplasty, mechanical scaffolding 
devices, and local drug-delivery systems (5). However, while the acute gain defined 
as the increment in minimal lumen diameter achieved at the end of the procedure 
increased, the interest in the net gain after mechanical and subsequent biologic 
remodelling at follow-up angiography was only marginally better. This indicates that 
the large acute gain obtained by those new devices evokes a very strong wound 
healing response that leads to a great late lumen loss. 
Numerous pharmacological agents have already been used effectively to inhibit 
this process of intimal hyperplasia in preclinical animal models (6). Based on the 
intended mode of action, these agents can be categorized into drugs that reduce recoil 
and spasm, inhibit platelet activation and thrombus formation, antagonize growth 
factors, inhibit (smooth muscle) cell proliferation, and prevent inflammation. 
However, in man no agent was found unequivocally effective as yet, although fish 
oil, and trapidil, a platelet-derived growth factor antagonist, and molsidomine, an 
inducer of nitric oxide release by endothelial cells, may have some favourable 
influence (7-9). The lack of efficient agents raises the question as to an explanation 
for all those failures. 
Unfortunately, we can only speculate why clinical trials were unsuccessful as yet. 
It could be relevant that the drug dose used in a number of trials was smaller than in 
the respective animal model (9). However, more importantly, it is questionable 
whether the animal models for restenosis really meet the human situation. It is 
noteworthy in this respect that, except for the Watanabe hypercholesterolemic rabbit 
(10), atherosclerosis in animals does not occur (9) and intimal hyperplasia is evoked 
by mechanical injury of an otherwise healthy artery. 
In the human situation other processes than wound healing may also account for 
restenosis considering established clinical risk factors, e.g., family history of 
coronary artery disease, unstable angina, current smoking and diabetes, that 
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determine if clinical restenosis occurs or not. One such process is the occurrence of 
compensatory reactions under pathological conditions. Recently, it became clear that 
in animal models (11) and in man (12) the diseased blood vessel increased in 
diameter in response to (partial) obstruction. However, if the artery fails to enlarge 
adequately in diameter to compensate for the intimal hyperplasia, the vessel will 
occlude. Which mechanisms underlie the process of vascular remodelling is not 
known. It could be that the adaptive enlargement is initiated by the increased wall 
shear stress that results from the initial stenosis (13). Alternatively, the support 
structure of the arterial wall is involuted by the developing plaque (11,12) or the 
release of proteolytic enzymes from inflammatory cells that accumulate in the lesion 
in response to injury (II). Therefore, an alternative strategy to prevent restenosis 
after angioplasty may be to promote the compensatory processes. Until this approach 
is successful, this leaves us with the option to knock-out the responsible (medial) 
smooth muscle cells at the site of the lesion directly. 
Photodynamic therapy of intimal hyperplasia 
The finding of Spears et al. (14) that porphyrins accumulate in atheromatous 
plaques and the observation that the photosensitizers are mainly taken up by rapidly 
proliferating and activated cells (15) focused the attention on photodynamic therapy 
(PDT) as a possible (adjunct) treatment modality for atherosclerosis (16-18) and 
restenosis (19-23). PDT has been developed as a treatment modality for malignancies 
and involves the cytocidal activity of a photosensitive dye after its activation by 
visible light (24). If the photosensitizer is excited, most commonly its energy is 
transferred via the photochemical type II reaction to oxygen which generates highly 
reactive singlet oxygen (25). Singlet oxygen is electrophilic and reacts with electron-
rich regions of biomolecules causing photodegradation of lipids, proteins, and 
nucleic acids, respectively, depending on the localization of the photosensitizer in the 
cell (26,27). The first photosensitizer with limited approval for clinical use is 
porfimer sodium (Photofrin ®), a mixture of oligomeric esters and ethers of 
hematoporphyrin and enriched in the photodynamically active fraction (24). 
Impressive complete response rates of various types of cancer have been obtained in 
Phase III trials including early stages of cancer of the lung, stomach, bladder and 
cervix (24). An inconvenient drawback of Photofrin is that it induces a transient skin 
photosensitivity. To avoid this problem and to improve treatment depth of PDT, 
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alternative so called second-generation photosensitizers have heen developed such as 
phthalocyanines, chlorins, purpurins, hacteriochlorins, verdins and protoporphyrin 
IX endogenously produced from exogenously administered 5-aminolevulinic acid, 
which currently enter clinical trials (28,29). 
The suitability of PDT for the prevention of restenosis has been studied so far in 
the balloon-injured rat carotid artery model using chloroaluminium sulphonated 
phthalocyanine (19,22) and 5-aminolevulinic acid induced protoporphyrin IX (23) as 
the photosensitizer. In the balloon-injured rabbit carotid (20) and iliac (21) artery 
model the photosensitizers Photofrin and hematoporphyrin derivative have been 
used, respectively. The consistent finding from these studies is that PDT (almost) 
completely inhibited intimal hyperplasia. The endothelial lining regenerated by two 
weeks after treatment, but the absence of smooth muscle cells in the treated media 
was striking. Despite the acellular media, the arterial segment remained patent (but 
non-contractile; 22), possibly due to the (singlet oxygen-mediated) crosslinking of 
collagen fibers of the matrix (30). Interestingly, recent evidence suggests that the 
addition of fluoride to chloroaluminium phthalocyanine makes PDT with this potent 
photosensitizer highly selective for smooth muscle cells without affecting endothelial 
cells (31). 
One of the earliest events after PDT treatment in vivo is the adhesion of 
granulocytes to the vessel wall (32). The mechanism underlying the adherence of 
granulocytes to the endothelial lining is not known. We found in an in vitro study 
that endothelial cells retract after PDT exposing the subendothelial matrix to which 
neutrophils readily adhere (33). The endothelial cells remain viable at least during the 
observation period of 30 min, and we show here that the constitutive release of the 
anti-adhesive factors NO and prostacyclin is not significantly decreased (Table 1). 
This latter finding seems in contrast with the study of Gilissen et al (34). They 
found that the endothelium-dependent relaxation of PDT-treated blood vessels in 
response to vasodilators such as acetylcholine decreased, while the endothelial lining 
of the vessel wall remained intact. The smooth muscle cells responded normally to 
administration of the exogenous NO donor nitroprusside. Apparently, PDT did 
decrease the release of NO by impairment of the muscarinic receptor for 
acetylcholine in the endothelial plasma membrane leaving the NO synthase itself 
intact. 
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Table I. Effect of Phototi'in-PDT of Human Umbilical Vein Endothelial Cells on the 
Release of Nitric Oxide and Prostacyclin l 
, 
Condition2 
Untreated 
Photorrin only 
Red light only 
Photorrin-PDT 
4.1 ±0.5 
4.0 ± 0.4 
4.3 ± 0.5 
4.2 ± 0.4 
49.3 ± 5.3 
32.7 ± 1.3 
50.7 ± 11.7 
32.5 ± 3.9 
Data are the means ± SD of tive (NO) or tlu'ee (PG!,) experiments. Assay of the 
supernatant was performed in triplicate (NO) or duplicate (PG!,). 
Endothelial cells were incubated for 20 hr with 25 ).lg/ml Phototi-in (Photofrin only; 
Phototi-in-PDT) and/or illuminated in a mirror box during 15 min with red light, 
which equals to 3.6 J/cm', delivered by a slide projector with a 250-W lamp (type 
7748S EHJ, Philips, Eindhoven, The Netherlands) and a cut-off filter «610 nm, 
#59512, Oriel Co., Stratford, CT) (Photofrin-PDT; red light only), or left untreated. 
Next, the endothelial cells were incubated for 30 min, after which the NO levels in 
the supernatant were assayed from the amount of nitrite using Griesz reagent, and 
the PGh levels tram the amount of 6-keto prostaglandin Fla, the stable hydrolysis 
product of PGh, which was determined with an enzyme inununoassay kit (Cayman 
Chemical Company, Ann Harbor, MI). 
It was observed that the neutrophils adhere to the subendothelial matrix 
exposed by PDT-treated endothelial cells via their ~2-integrin receptors, which 
were subsequently activated by a direct interaction with matrix proteins (33). The 
endothelial cells probably do not mediate this activation, since we show here that 
P-selectin, the most likely candidate of the endothelial membrane receptors that 
can activate the ~2-integrin receptor of the neutrophil (35), was not upregulated by 
PDT-treatment (Figure I). A photosensitized release of von Willebrand factor 
from human umbilical vein endothelial cells has previously been shown to occur 
after I hr (36) and this is accompanied by a rapid distribution (without de novo 
synthesis) to the cell membrane of P-selectin (37). However, von Willebrand factor 
was not detected within 30 min after PDT either (Figure 1), while histamine 
stimulated both the release of von Wille brand factor and the expression of P-
selectin considerably after 30 min (Figure 1). PDT also did not stimulate the 
expression E-selectin and members of the immunoglobulin superfamily, including 
rCAM-! and -2, PECAM-! and VCAM-! (not shown). Since an increased 
expression of these cellular adhesion molecules is dependent on de novo synthesis, 
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this finding is not surprising with respect to the limited time frame of our study. 
Control 
PDT 
Histamine 
0.00 0.25 0.50 
OD450 
0.75 1.00 
Figure 1. Effect of Photolrin-PDT (25 )lg/rnl Photofrin for 20 hr, followed by illumination in 
a mirror box during 15 min with red light, which equals to 3.6 J/cm2, delivered by a 
slide projector with a 250·W lamp (type 7748S EHJ, Philips, Eindhoven, The 
Netherlands) and a cut-off filter «610 nm, #59512, Oriel Co., Stratford, CT), and 
histamine (10.5 M) on the release of von Willebrand factor (white bar) and the 
expression of P-selectin (grey bar) assayed by ELISA after 30 min by human 
umbilical vein endothelial cells. Each bar represents the mean ± SD of three 
determinations. 
Taken together, this indicates that PDT-treated endothelial cells only play a 
passive role in the increased adherence of neutrophils to the subendothelial matrix. 
What is the relevance of this finding for the PDT treatment of balloon-injured 
coronary arteries? In the next section we will show that neutrophils may have an 
important role in tissue healing after coronary angioplasty. 
Role of neutrophils iu decreasing late lumen loss 
Some years ago, Libby et al (38) proposed an important role of blood monocytes 
in the cascade of events that lead to smooth muscle migration and proliferation into 
the intima. By the early acute release of cytokines those phagocytes evoke a 
secondary cytokine and growth factor response from other types of cell in the lesion. 
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This might establish a positive, self-stimulatory autocrine and paracrine feedback 
loop amplifying and sustaining the proliferative response of the smooth muscle cells. 
Neutrophils are first-line defenders against invading pathogens. Since the early 
1980s it became known that neutrophils also mediate tissue destruction in 
inflammatory diseases such as ischemic heart disease (39). Considering this, it was 
anticipated that neutrophils have a potential bearing in the vascular lesion after 
angioplasty. That prompted us to study the relationship between the late lumen loss 
and the activation state of both types of phagocyte before angioplasty. 
The results showed that the amount of interleukin(~)-I ~ that was synthesized by 
the patients' monocytes upon stimulation in vitro is positively associated with the 
extent of late lumen loss (40). This characteristic is genetically determined (41) and 
its magnitude depends also on the primed state of the monocyte (42). Surprisingly, 
the activation state of neutrophils as reflected by an increased expression of the 
membrane receptors C064 and C066, was inversely associated with late lumen loss 
(40). This indicated that activated neutrophils in fact could serve a beneficial role in 
tissue healing after ITCA. We can only speculate on the relevant factors in this 
process. C064 is the high affinity receptor for immunoglobulin G. It was found 
recently that the C066 receptor serves as a presenter molecule of the sialylated 
Lewis(x) antigen, which binds to the endothelial leucocyte adhesion molecule-Ion 
cytokine-activated endothelial cells (43). Therefore, an increased expressiou of the 
C066 receptor may be of particular interest for the accumulation of the neutrophils 
at the site of the lesion. Neutrophils can generate 6-keto-prostaglandin-El and 13-
hydroxyoctadecadienoic acid, which are inhibitors of platelet aggregation and 
platelet adhesion, respectively (44). By the release of these inhibitors local 
thrombosis after PTCA may be prevented, which is considered as a key event in the 
initiation of intimal hyperplasia (38). Furthermore, neutrophils may also contribute to 
hydrolysis of extracellular matrix components and subsequent compensatory 
vascular remodelling by the release of (metallo)proteinases. 
Conclusion 
An important clue why PDT so effectively inhibits intimal hyperplasia may come 
from the observation that activated neutrophils prevent late lumen loss after coronary 
angioplasty (40). Clearly, after PDT of the diseased vessel all smooth muscle cells in 
the media were killed, but why the media did not become repopulated is a matter of 
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speculation. We found that after PDT neutrophils rapidly adhere to the 
subendothelial matrix of the vessel wall (33). These phagocytes can generate potent 
inhibitors of thrombosis thereby preventing the release of chemotactic factors for 
smooth muscle cells from activated platelets (44). On the other hand 
(metallo )proteinases released by these neutrophils can hydrolyse extracellular matrix 
components of crucial importance for the migration of smooth muscle cells into the 
media. 
A seeming contradiction for an important role of neutrophils is the observation 
that inflammatory cells were absent from day 7 after PDT -treatment of the 
balloon-injured artery (22). However, since the acute inflammatory reaction in 
response to vascular injury lasts only for 2-4 days (3), it is not surprising that no 
inflammatory cells were seen at day 7. 
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CHAPTER 4 
Evidence for an important role of neutrophils 
in the efficacy of photodynamic therapy in vivo 
Wil J.A. de Vree, Maria C. Essers, Henriette S. de Bruijn, 
Willem M. Star, Johan F. Koster, and Wim Sluiter. 
(Cancer Research 56: 2908-2911, 1996) 
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Abstract 
To investigate the role of neutrophils in the efficacy of photodynamic therapy 
(PDT) in rhabdomyosarcoma-bearing rats, the number of these circulating 
phagocytes was decreased or increased before interstitial PDT by use of rabbit 
anti-rat neutrophil serum or granulocyte-colony stimulating factor (G-CSF), 
respectively. After administration of the antiserum the number of circulating 
neutrophils decreased by 99.9%. However, the numbers of monocytes, 
lymphocytes and platelets decreased as well (by 100%, 80%, and 25%, 
respectively). Under these conditions PDT did not retard tumor growth at all. 
However, after cessation of the antiserum treatment 5 days after PDT a striking 
decrease in growth rate occurred subsequent to an increase above the normal range 
of the number of circulating neutrophils. 
Administration of G-CSF led to a specific four-fold increase in the numbers of 
circulating neutrophils. In these rats the tumor growth at day two after PDT was 
retarded as compared with PDT treated rats that received saline only. 
Statistical evaluation of both experimental conditions showed that the efficacy 
of PDT, expressed as the percentual change in tumor volume at day 2 after 
treatment, was dependent on the number of circulating neutrophils present at the 
day of PDT (P=O.OOI, R2=0.482). Apparently, neutrophils are indispensable for 
succesfull PDT in vivo. 
Introduction 
The mechanisms that play a role in tumor eradication after Photofrin-based 
photodynamic therapy (PDT) are subject to extensive study. The first event 
occuring after illumination of a photosensitiser is the formation of very reactive 
oxygen species (ROS) such as singlet oxygen (1-3). These ROS are involved in 
direct tumor cell death by oxidation of plasma membranes, mitochondria and 
Iysosomes (4,5). However, tumor cells are killed mainly indirectly by the effect of 
Photofrin-based PDT on the normal and tumor vasculature. Henderson et al. (6-8) 
clearly showed that the kinetics of the loss in tumor cell c!onogenicity in vivo 
coincided with the late blood flow stasis leading to deprivation of the tumor from 
oxygen and nutrients. The mechanisms underlying the effect of PDT on the 
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(tumor) vasculature are not fully elucidated as yet. It is well established that 
endothelial cells are very sensitive to PDT (9,10). These cells not only rapidly 
loose their ability to relax upon acetylcholine stimulation after PDT (II), which 
leads to vasoconstriction, but also contract themselves, as has been observed in 
vivo (12) and in vitro (13), exposing the thrombogenic subendothelium. This will 
stimulate edema formation, platelet aggregation, thromboxane release and 
thrombus formation finally leading to blood flow stasis with subsequent regression 
of the tumor (10,14-17). 
There is growing evidence that an inflammatory reaction by immuno-competent 
leucocytes might playa role in tumor destruction after PDT as well. Neutrophils 
adhere to the vascular wall (18) and infiltrate the tumor area after PDT (19). 
Moreover, several immunotherapentic approaches have been reported to potentiate 
the effects of PDT (20-23). In this study we investigated the relationship between 
the number of nentrophils in the circulation and the efficacy of PDT as determined 
by the effect on growth rate of the rat rhabdomyosarcoma R-l in vivo. To this end, 
the numbers of blood neutrophils were decreased by use of rabbit anti-rat 
granulocyte serum or increased by granulocyte-colony stimulating factor (G-CSF) 
before the start of PDT. 
Materials and Methods 
Animals and tumor model 
Female WAG/Rij rats, aged 12-20 weeks, were obtained from Harlan (Zeist, 
The Netherlands). Small pieces of a well characterized isologous 
rhabdomyosarcoma, designated as R-I (24) were implanted subcntaneously into 
both thighs. Tumor growth was assessed by caliper measurements on three 
orthogonal diameters, at least three times a week. Tumors were treated when the 
volume was between 1200 and 2000 mm3 • Blood samples were obtained from a 
tail vein with EDT A as the anticoagulant. Total leucocyte counts were determined 
with a microcell counter, and differential counts were carried out on May-
GrUnwald and Giemsa-stained blood smears. 
49 
Photosensitizer and drugs 
The photosensitizer Photofrin II'" (PIl) was obtained from Quadra Logic 
Technologies Inc. (Vancouver, BC, Canada) and was reconstituted in 5% glucose 
before use. The photosensitizer was administered i.v. into a tail vein at 10 mg 
PIIIkg 24 hr prior to light delivery. 
Polyc1onal rabbit anti-rat granulocyte antiserum was purchased from Accurate 
(Westbury, NY, USA) and lyophilized recombinant human G-CSF was purchased 
from Amersham International (Buckinghamshire, England) and dissolved in saline 
(0.9%) containing I % normal rat serum (NRS; Central Laboratory for 
Bioodtransfusion, Amsterdam, The Netherlands). 
Light delivery 
The light source was a dye laser pumped by an Argon ion laser (Spectra 
Physics model 375B and 2040E, respectively). A birefringent filter and 
monochromator were used to tune the dye laser to emit light at 625 ± I nm 
wavelength using DCM (4-dicyanomethylene-2-methyl-6(P-dimethylaminostytyl)-
4H-pyran) as a dye. The light was directed via a beam splitter to three cylindrical 
diffusers of IS mm length (Rare Earth Medical, Dennis, MA, USA). 
Treatment protocol 
In the first series of experiments, rats were administered 2 mllkg granulocyte 
antiserum by i.p. injection at 2 days before PDT treatment, followed by daily i.p. 
injections of 0.5 ml/kg antiserum for 6 consecutive days. Control rats were 
injected with equal volumes of saline. In the next series of experiments, 7.5 f.lg/kg 
G-CSF containing 1% NRS was injected i. v. at 9 hr before and 9 hr and 27 hr after 
PDT treatment. Control rats were injected with equal volumes of saline containing 
I%NRS. 
Interstitial PDT treatment was performed as previously described (25) with 
minor adaptations. In brief: rats were anaesthetized by i.m. injection of I mllkg 
Hypnorm (fluanisollfentanyl mixture; Janssen Pharmaceutica, Beerse, Belgium). 
Animals were placed on a heated support during treatment to control body 
temperature. In one of both tumors a diffussor was inserted into the central axis of 
the tumor parallel to the body axis. In the contralateral tumor a dummy was placed. 
The output of the diffuser was kept below 50 m W per cm of diffuser length to 
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avoid hyperthermic effects. Tumor core temperature was measured during PDT 
using a thermocouple probe and never exceeded 40"C. Total applied radiant energy 
was 270 J per cm of diffussor length. This treatment modality resulted in delay of 
tumor growth, but not in tumor regression. At the end of the observation period 
rats were sacrified and sections of tumor tissue were hematoxylin-eosin stained 
according to standard histologic procedures. 
Statistical analysis 
Data were analysed by paired or unpaired Student's t-test and Pearson 
correlation analysis where appropriate and considered significant when P < 0.05. 
Results 
Effect of anti-granulocyte antiserum on tumor growth after photodyuamic 
therapy 
To evaluate the effect of anti-granulocyte antiserum on tumor growth after 
PDT, the numbers of neutrophils, monocytes, lymphocytes, and platelets were 
determined first. We found that one day after the start of antiserum administration 
the neutrophils were depleted by 99.9% (see Table I). The number of neutrophils 
remained at that low level until the administration of antiserum was stopped. The 
antiserum was not specific for neutrophils, because the number of blood 
monocytes, lymphocytes and, to a lesser extend, the platelets were decreased as 
well, i.e., by 100%, 80% and 25%, respectively (Table I). 
To investigate if the condition induced hy the administration of the antiserum 
interferes with tumor growth or the efficacy of PDT, the tumor volumes of control 
and PDT treated tumors were determined at various time-points (Figure I). As 
shown, the growth rate of the control tumors of the antiserum treated rats were not 
significantly different from the control tumors of the saline treated rats. The 
current PDT treatment resulted in a delay of tumor growth for five days in saline 
treated rats (Figure I). However in the antiserum treated rats PDT did not 
influence tumor growth significantly. Statistical evaluation showed irrespective of 
antiserum treatment an inverse association between the percentual increase of 
tumorvolume at day 5 after PDT and the number of neutrophils (P=0.004, 
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R'=O.663) and lymphocytes (P=O.OII. R'=O.573) present in the circulation at the 
day of PDT. 
Table 1. Effect of administration of anti-granulocyte antiserum on the number of blood 
cells. 
Type of cell Antigranulocyte antiserum Saline 
(X lO9/liter) Start I Day later Start 1 Day later 
Neutrophils 1.49 ± 0.4" 0.001 ± 0.003" l.l8 ± 0.4 1.35 ± 0.22 
Monocytes 0.12 ± 0.08 ND' 0.16 ± 0.07 0.14 ± 0.09 
Lymphocytes 10.2 ± 2.2 2.0 ± 0.7" 9.5 ± 1.6 8.1 ± 1.2 
Platelets (X lOl2/liter) 877 + 93 656 + 77" 746+ 189 891 + 58 
(/ Data are the means ± SD of five rats. 
b Data are significantly different (P < 0.005) from the normal number at the start 
of administration. 
,. ND, not detectable. 
d Data are significantly different (P < 0.05) from the normal number at the start 
of administration. 
800 f 
~ / 
w /T~f :E ;0 
...J 
0 T~O /'" > 
'" ~ 0 < VT :E ;0 ... zo _______ 
100 
80 
0 6 
TIME AFTER PDT (DAYS) 
Figure I. Effect of anti-granulocyte antiserum on tumor growth after PDT. Volumes of 
PDT-treated (open circle) or control (closed circle) tumors of rats injected with 
antiserum and of PDT-treated (open square) or control (closed square) tumors of 
rats injected with saline are expressed as percentage of the tumor volume at the 
day of treatment. Data are the means ± SD of five rats. 
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Strikingly, after the administration of antiserum was stopped (at day 5 after 
PDT treatment), a delay in tumor growth was observed. This was preceded by an 
increase to about the normal level of circulating monocytes (70%), lymphocytes 
(112%), and platelets (116%), while the number of neutrophils increased even 
further to approximately a factor 9.5 above the normal range. Statistical analysis 
showed that the percentual increase in tumorvolume during that time for all the 
PDT treated tumors inversely correlated with the increase m the number of 
neutrophils (P=0.0l5, R2=0.593), but not with the increase in the numher of 
monocytes, lymphocytes or platelets. 
Effect of G-CSF on tumor growth after photodynamic therapy 
If the growth rate of PDT treated tumors indeed depends on the number of 
neutrophils in the circulation, increasing the number of blood neutrophils before 
PDT should amplify the efficacy of tumor treatment. To study this, G-CSF was 
administered i.v. 9 h before and 9 hand 27 h after PDT. This led to a fourfold 
increase in the number of circulating neutrophils at the start of PDT, while the 
numbers of monocytes, lymphocytes and platelets stayed within the normal range 
(Table 2). 
Table 2. Effect of administration of G-CSF on the number of blood cells. 
--~-
Type of cell G-CSF Saline 
.JE1.9)liter) Start 9 h later Start 9 h later 
Neutrophils 1.3 ± 0.3" 6.1 ± 0.9" 1.7 ± 0.6 2.0 ± 0.8 
Monocytes 0.16 ± 0.08 0.2 ± 0.08 0.18 ± 0.04 0.14 ± 0.D9 
Lymphocytes 8.3 ± 0.9 7.6± 0.9 8.2 ± 1.5 6.7± 1.9 
Platelets (X 1012/liter) 853 + 175 898 + 148 901 + 85 844 + 85 
II Data are the means ± SD of five rats. 
b Data are significantly different (P < 0.001) from the normal number at the start 
of G-CSF injection. 
Under this condition the growth rate of control tumors was not changed, but 
PDT was more effective as compared to saline controls up to and including day 2 
after PDT (Figure 2). Thereafter, the PDT treated tumors of both the G-CSF and 
saline treated animals resumed growth at a similar rate, which did not differ from 
the control tumors (Figure 2). Statistical analysis showed an inverse relationship 
between the percentual increase in tumor volume at day I and the number of 
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neutrophils (P=O.OOI, R2=O.792) and lymphocytes (P=O.005, R'=O.699) at the day 
of treatment. 
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Figure 2. Effect of G-CSF on tumor growth after PDT. Volumes of PDT-treated (open 
circle) or control (closed circle) tumors of rats injected with G-CSF and of PDT-
treated (open square) or control (closed square) tumors of rats injected with 
saline are expressed as percentage of the tumor volume at the day of treatment. 
Data are the means ± SD of five rats. 
Evaluation of the data from both experiments (Figure 1 and 2) by Pearson 
correlation analysis confirmed that the effect of this PDT treatment modality on 
the growth rate of the tumors at day 2 after therapy, depended on the number of 
neutrophils (P=O.OOI, R2=0.482), while there was no significant relationship with 
the number of monocytes, lymphocytes or platelets. 
Histologic examination of tumor tissue 
At the end of the observation period rats were sacrified and tumor tissue was 
examined. The analysis of the PDT treated tumors of all rats showed vital 
rhabdomyosarcoma tissue next to necrotic tumor tissue. On the border of these 
vital and necrotic areas, large infiltrates of leucocytes were observed which mainly 
consisted of neutrophils (Figure3). 
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Figure 3. Histologic examination of tumor tissue. Tissue sections of PDT treated tumors of 
all rats were hematoxylin-eosin stained. Shown is a typical infiltrate at the border 
of vital and necrotic tumor tissue, mainly consisting of neutrophils. 
Magnification: 200X. 
Discussion 
The major finding of this study was that the efficacy of PDT in vivo is 
dependent on the number of neutrophils in the circulation. In the absence of 
neutrophils, a condition achieved by the administration of anti-granulocyte 
antiserum, PDT had no effect on tumor growth, while an increase in the number of 
neutrophils upon G-CSF administration before PDT led to a (temporary) increase 
in the efficacy of PDT. 
In literature there are several reports that point at a role for neutrophils in 
combination with PDT. The adhesion of granulocytes to the vascular wall is one of 
the first events to occur after PDT (18). This observation was confirmed by our 
group and we proposed a mechanism that may underly the adherence of 
granulocytes to the vascular wall after PDT (13). Recently neutrophils were also 
reported to rapidly infiltrate squamous cell carcinoma after treatment by PDT (19). 
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Moreover, upregulation of the activation status of the immune system as reflected 
by the number of Mac-l positive cells by the immunostimulant schizophyllan 
before PDT led to a three-fold decrease in colony forming tumor cells in vitro as 
compared to PDT only (20). From the data presented here we conclude that 
apparently the neutrophils determine the outcome of tumor regrowth after PDT in 
vivo. 
We postulate that neutrophils might adhere via ~2-integrins to stretches in the 
vascular wall where endothelium as a result of PDT has contracted (13) and where 
the subendothelial matrix is exposed as has been reported previously (I2). 
Neutrophils, most likely attracted by chemotactic factors, could infiltrate the 
tumor-area releasing proteolytic enzymes that degrade attenuated tumor cells, 
which otherwise may continue to proliferate. 
Direct tumor cell eradication by oxidative stress is limited to a short time-frame 
since very soon after the start of PDT vasoconstriction (11), platelet aggregation 
and blood flow stasis has been observed (15), inhibiting further oxygen transport 
to the tumor area. Although this in fact prevents an efficient PDT, it turns into 
good because vessel occlusion deprives the tumor from its essential supply of 
oxygen and nutrients. In this manner tumor cells that have escaped the direct kill 
by oxidative processes will be attenuated still. It is generally accepted that this 
effect on the vasculature is indispensable for tumor regression after Photofrin-
based PDT, and that platelets play an important role therein (3). Our study does 
not argue against this concept since we suppose here that the attenuation of the 
tumor cells is a prerequisite before neutrophils are able to destroy them. However, 
how this condition is achieved, either directly during PDT or later as a result of 
vessel occlusion, possibly does not matter and depends on the type of 
photosensitizer. This is substantiated by our finding that neutrophils are not able to 
retard the growth rate of control tumors while these phagocytes were increased in 
number by the administration of G-CSF (Figure 2, closed circle). In seeming 
contradiction to this idea is the finding of Fingar et at. (26) that inhibition of the 
release of thromboxane by indomethacin not only prevents PDT-induced vascular 
stasis but also destruction of the (chondrosarcoma) tumor. While under those 
conditions the direct killing potential of PDT would be fully utilized because of 
the uninterrupted supply of oxygen, the failing PDT treatment apparently stresses 
the sole importance of the vascular effect. However, neutrophils as the final 
effector cells need to become fully activated by factors like G-CSF that can be 
produced by e.g. endothelial cells, monocytes/macrophages, lymphocytes and 
platelets (27,28). And indomethacin, like other nonsteroidal anti-inflammatory 
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drugs, not only inhibits the release of thromboxane (26), but also inhibits the 
activation of the neutrophil (29). Therefore, these phagocytes were not able to 
erradicate the directly injured tumor cells. In keeping with this idea is the striking 
finding of the present study that PDT treated tumors under neutropenia still remain 
vulnerable to eradication by neutrophils for a long time after treatment. Namely, 
when five days later the administration of antiserum was stopped, which 
subsequently led to a tenfold increase of neutrophil numbers, tumor growth still 
retarded (Figure I, open circle). 
Recently, Dellian et al. (30) showed that the number of leucocytes that adhered 
to the tumor microvessel wall of the amelanotic melanoma A-Mel-3 within 3 h 
after PDT was small. Also Wu et aE. (31) found a diminished leucocyte-
endothelium interaction in tumor microvessels. These findings may seem in 
contrast with the present study. However, we found large infiltrates mainly 
consisting of neutrophils present in all PDT treated Rhabdomyosarcoma tumors at 
the end of the observation period. Taken together, we conclude that neutrophils are 
indispensable for efficient PDT in vivo. 
The use of G-CSF could be a promising accessory modality to improve the 
efficacy of PDT. G-CSF is a haematopoietic growth factor which principally 
stimulates the proliferation and differentiation of specifically neutrophil progenitor 
cells by binding to high-affinity G-CSF-specific receptors on their cell membranes 
(32). This is confirmed by our findings as well (cf. Table 2). It also increases the 
activities of mature neutrophils, including chemotaxis, phagocytosis, and oxidative 
metabolism (28). Furthermore, recombinant human G-CSF is now commercially 
available and approved (Filgrastim) or in phase IV clinical trial (Lenograstim) 
(33,34). On this basis further study on the optimal dose and duration of G-CSF 
administration as an accessory treatment to improve PDT is warranted. 
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CHAPTERS 
Role of interleukin 1 and granulocyte colony-stimulating 
factor in photofrin-based photodynamic therapy of rat 
rhabdomyosarcoma tumors 
Wil 1.A. de Vree, Maria C. Essers, lohan F. Koster, and Wim Sluiter. 
(Cancer Research 57: 2555-2558, 1997) 
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Abstract 
Neutrophils play an important role in the efficacy of photodynamic therapy 
(PDT). Those leukocytes rapidly accumulate into the tumor lesion after PDT and 
most likely eradicate the remaining attenuated tumor cells. The underlying 
mechanism of the accumulation of neutrophils upon PDT is not known. Therefore, 
we determined the effect of PDT on the course of mature and immature 
neutrophils in the circulation of rhabdomyosarcoma-bearing rats, and studied the 
changes in the level of interleukin(IL)-1 ~ as an important stimulator of the 
proliferation of precursor cells of the granulocyte lineage in the bone marrow. 
We found that the effect of PDT on tumor growth was preceded by a rapid and 
specific increase of the number of mature neutrophils in the peripheral blood as 
early as 4 h after the start of PDT treatment and reaching maximum values after 8 
h. At 24 h the neutrophil numbers in the PDT-treated rats were still elevated as 
compared to sham-treated rats. In sham-treated rats the numbers of blood 
monocytes and lymphocytes decreased by about 50% after 2 h and returned to their 
normal levels as soon as 2 h later. In PDT-treated rats the course of monocyte 
numbers showed a similar pattern. However, lymphocyte numbers did not reach 
the normal range until 24 h. 
The specific increment of neutrophils was preceded by an increase of band 
neutrophil numbers and elevated serum levels of IL-l ~ being maximal at 2 h after 
the start of PDT. Pearson correlation analysis showed a significant association 
between the serum levels of IL-l~ at this time point and the number of band 
neutrophils at 4 h (R'=0.58, p=0.03) and the number of mature neutrophils at 8 h 
(R2=0.54, p=0.04). This suggests that PDT evoked an IL-l-dependent increased 
production rate of neutrophils in the bone marrow. Further investigation showed 
that the injection of anti granulocyte-colony-stimulating-factor(G-CSF) antibodies 
not only attenuated the increase in neutrophil numbers, but also greatly decreased 
the efficacy of PDT. On this basis we suppose that an IL-l-induced release of G-
CSF by PDT underlies this nonspecific immune reaction to the tumor. Apparently, 
G-CSF not only stimulates the production rate of neutrophils in the bone marrow, 
but also increases the functional activity of those leukocytes to become the 
indispensable tumor cell killers. 
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Introduction 
Increasing evidence arises that besides direct tumor cell kill due to formation of 
singlet oxygen (1) and indirect tumor cell kill as a result of deprivation of oxygen 
and nutrients due to vaso-occlusion (2) PDT also elicits a nonspecific (3,4) and a 
specific immune response directed to the tumor (5). A central role in this immune 
response might be performed by the endothelial cells which contract upon PDT as 
has been observed in vivo (6) and studied in vitro (7), exposing the thrombogenic 
subendothelium. Besides the fact that this endothelial contraction stimulates edema 
formation, platelet aggregation, thromboxane release and thrombus formation 
which eventually leads to blood flow stasis (8,9), it also will facilitate the 
extravasation of blood leukocytes into the underlying tumor tissue. 
Very soon after the start of PDT neutrophilic granulocytes adhere to the 
vascular wall (10) and infiltrate the tumor area (\ 1) where they may kill the 
attenuated tumor cells directly (\2) or via a complex interaction with other cells 
(\3). The concept that leukocytes may play an important role in the PDT-induced 
inflammatory reaction has led to several immuno-therapeutic approaches in order 
to enhance the efficacy of PDT (4, 14-16). These strategies indeed potentiated the 
effect of PDT, stressing the important role of a cellular inflammatory reaction in 
tumor kill. 
Since we have shown recently that an effective interstitial PDT of 
rhabdomyosarcoma tumors is dependent on the presence of neutrophils in the 
circulation (3), the question was raised whether PDT by itself influences the 
number of blood neutrophils. In the present study we therefore established the 
effect of PDT on the course of neutrophils in the circulation of rats bearing 
rhabdomyosarcoma R-l tumors and examined the underlying regulatory 
mechanism. 
Materials and Methods 
Animals and tumor model 
Female W AG/Rij rats, aged 10-\5 weeks, were obtained from Harlan (Zeist, 
The Netherlands). Small pieces of a weB characterized isologous rhabdomyosarco-
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ma, designated as R-l (17) were implanted subcutaneously into the thighs. Tumor 
growth was assessed by calliper measurements on three orthogonal diameters, once 
a day. Tnmors were treated when the volume was between 750 and 1500 mm3 
Blood samples were obtained by tail bleeding with EDTA as the anticoagulant. 
Total numbers of leukocytes were determined with a microcell counter. 
Differential counts were performed on May-GrUnwald and Giemsa-stained blood 
smears in quadruplicate. 
Photosensitizer and light delivery 
The photosensitizer Photofrin I!® (pm was obtained from Quadra Logic 
Technologies Inc. (Vancouver, BC, Canada) and was reconstituted in 5% glucose 
before Lv. administration into a tail vein at 10 mg PIIIkg 24 h prior to light 
delivery. 
The light source was a dye laser pumped by an Argon ion laser (Spectra 
Physics model 375B and 2040E, respectively). A birefringent filter and 
monochromator were used to tune the dye laser to emit light at 625 ± 1 nm 
wavelength using DCM (4-dicyanomethylene-2-methyl-6(P-dimethylaminostytyl)-
4H-pyran) as a dye. The light was directed via a beam splitter to three cylindrical 
diffusers of 15 mm length (Rare Earth Medical, Dennis, MA, USA). 
Treatment protocol 
Interstitial PDT treatment was performed as previously described (3) with 
minor adaptations. In brief: rats were anaesthetized by i.m. injection of 1 m1/kg 
Hypnorm (fluanisol/fentanyl mixture; Janssen Pharmaceutica, Beerse, Belgium). 
Animals were placed on a heated support during treatment to control body 
temperature. A diffusor was inserted into the central axis of the tumor parallel to 
the body axis. The output of the diffuser was kept below 50 mW per cm of diffuser 
length to avoid hyperthermia. Tumor core temperature was measured during PDT 
using a thermocouple probe and never exceeded 40"C. Total applied radiant energy 
was 270 J per cm of diffusor length. Control rats were treated in the same way as 
above apart from the illumination protocol (i.e. PIT injection only) or PI! injection 
(i.e. illumination only). 
For studies on the involvement of growth factors, rats were injected with 500 
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mg of sheep polyclonal antibody against recombinant human (rh) G-CSF 
(Biodesign International, Kennebunk, ME, USA) i.v. 1 h prior and i.p. 8 h after the 
start of PDT treatment. 
Cytokine ELISA 
ILl-~ and TNF-o: levels in sera were determined by rat specific ELISA kits 
obtained from Biosource (Biosource Europe S.A., Fleurus, Belgium). 
Statistical analysis 
Data were analysed by paired or unpaired Student's t-test and by Pearson 
correlation analysis where appropriate and considered significant when P < 0.05. 
Results 
Effect of PDT on tumor growth 
To study the effect of PDT on the number of neutrophils in the circulation, we 
evaluated the efficacy of the applied PDT treatment on the growth of 
Rhabdomyosarcoma tumors first. As shown in Figure I tumor growth of rats 
treated with PH or illumination only was not affected whereas PDT treatment did 
affect tumor growth. Strikingly, one day after PDT treatment the tumor volumes 
were significantly increased as compared to illumination (P=0.025) or PH 
(P=O.OI6) only. However, at two days after PDT treatment the tumor volumes 
were decreased to approximately the original volume at the start of treatment. At 
this point tumor growth after PDT treatment was significantly retarded as 
compared to the control tumors. The growth delay (i.e. the time that is needed for a 
tumor to reach its original treatment volume) was approximately 4.5 days. 
Thereafter tumor growth resumed at the same rate as before the start of PDT. 
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Figure 1. Tumor growth of Rhabdomyosarcoma after PDT. Volumes of PDT-treated 
tumors (open circle), of unilluminated tUmors of rats injected with PI! (closed 
circle), and of illuminated tumors of rats without PI! injection (open square) are 
expressed as percentage of the tumor volume at the day of treatment. Data are the 
means of five rats; bars, SD. 
Effect of PDT on the numerical course of blood leukocytes 
After PDT or control treatment the number of circulating lymphocytes (Figure 
2a) decreased at 2 h to about 50% of the original number at the start of treatment. 
Thereafter their numbers increased again to approximately the normal level after 8 
h for the control groups and after 24 h for the PDT treated group. The number of 
monocytes decreased also transiently to about 50% of the original value at 2 h 
after PDT or control treatment, reaching the pre-treatment level 2 h later 
irrespective of the type of treatment (Figure 2b). The number of neutrophils 
changed dramatically upon treatment (Figure 2c). From 4 h after treatment onward 
their number increased four-fold in both control groups to a maximum at 8 h after 
treatment, while PDT treatment even led to a five-fold increase which was 
significantly higher than the control groups (P<0.02). At 24 h neutrophil numbers 
were decreased to the normal level in the control rats, while being still elevated in 
the PDT treated rats. Strikingly, immature band neutrophils appeared in the 
circulation as early as 2 h upon PDT treatment, reached a maximal number of 
0.081 ± 0.08 x 109/L at 4 h post PDT, and subsided thereafter to below the 
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detection limit (not shown) 
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Figure 2. Effect of treatment on the numbers of peripheral blood leukocytes. Shown are the 
numerical courses of lymphocytes (A), monocytes (B), and neutrophils (C) after 
treatment of rat rhabdomyosarcoma tumors by PDT (open circle), or injection 
with PI! (closed circle) or illumination only (open square). Data are the means of 
fIve rats; bars, SD. 
Effect of PDT on serum levels ofIL-l/3 and TNF-a 
To investigate the regulatory mechanism of the PDT -induced increase III the 
number of blood neutrophils, we determined the occurrence of the 
proinflarnmatory cytokines !L-t /3 and TNF-a in the sera of control and PDT 
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treated rats (Figure 3). We found a transient, but significant increase in IL-l~ 
levels with a maximum at 2 h after PDT as compared to the level in control treated 
animals (p<O.05). Pearson correlation analysis showed a treatment-independent 
relationship between the serum level of IL-l at 2 h and the number of band 
neutrophils at 4 h (R2=O.58, p=O.03) and the number of mature neutrophils at 8 h 
(R2=O.54, p=O.04). The levels of TNF-a were below the detection limit and did not 
change upon PDT or control treatment. 
Figure 3. ElIect of PDT on serum IL-l~ levels. Shown are the serum levels ofII.-l~ of rats 
treated by PDT (open circle), or injection with PI! (closed circle) or illumination 
only (open square). Data are the means of five rats; bars, SD. 
Involvement of G-CSF 
To examine whether the increase in the level of IL-l ~ directly underlies the 
observed neutrophilia, we injected polyclonal anti-G-CSF antibody at time zero 
and at 8 h after the start of PDT. As shown in Figure 4a this antibody treatment 
attenuated the PDT-induced numerical increase in blood neutrophils. If expressed 
as the area-under-the-curve of blood neutrophils (dimension: 109xL,lx24h) during 
the observation period of 24 h, these two consecutive injections of anti-G-CSF 
antibodies led to a decrease of about 25%, i.e., from 118.6 to 87.1. In contrast to 
the moderate effect on the numerical course of neutrophils in the circulation, this 
anti-G-CSF treatment led to a dramatic decrease in the efficacy of PDT amounting 
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to an estimated delay of tumor growth of about one day as compared to 4.5 days 
under the normal condition (Figure 4b). 
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Figure 4. Involvement of G-CSF in the PDT induced neutrophilia. Shown are the courses 
of neutrophils in the circulation (A) and tumor volumes (B) of rats atter PDT 
treatment (open circle; n=5) or after PDT treatment in the presence of polyclonal 
anti-G-CSF antibody (closed circle; n=2). For comparison (B), the tumor 
volumes of rats atter PDT treatment (open circle) and of rats injected with PII 
only (open square;data of Figure I) are shown. 
Discussion 
The major finding of this study was that interstitial PDT elicited a severe 
inflammatory reaction characterized by a profound neutrophilia that appeared 
dependent on an IL-l-induced release of G-CSF. Sham-treatment of the tumor-
bearing rats induced a (moderate) increase in the number of blood neutrophils as 
well, which was possibly evoked by tissue damage upon insertion of the optic 
fiber. However, this did not lead to retardation of tumor growth. Apparently, 
neutrophils are not able to kill those vital tumor cells directly. This confirms the 
results of a previous study showing that a direct effect of PDT on the tumor is 
necessary for neutrophils to become effective in tumor cell eradication, while in 
the absence of neutrophils PDT on its tum is also not effective (3). 
It is noteworthy that the increase in the number of blood neutrophils after PDT 
most likely is an underestimation of the magnitude of the inflammatory reaction. 
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Due to the migration and accumulation of neutrophils upon PDT into the tumor 
area (3,11) the half-time of neutrophils in the circulation will decrease 
accordingly. Furthermore, by inducing the contraction of the endothelial cells 
lining the vessel wall PDT treatment may also facilitate the accumulation of the 
neutrophils in the tumor. Indeed, exposure of the subendothelial matrix by PDT 
promotes the adhesion of neutrophils (7), and may also lead to edema formation 
explaining the temporary increase of the tumor volumes at one day after PDT 
treatment (Figure I). 
We found here that the peak in the number of mature blood neutrophils was 
preceded by a peak in the appearance of immature band neutrophils in the 
circulation indicating that the production rate of neutrophils in the bone marrow is 
increased as well. This could be brought about by IL-l that occurred in the 
circulation during the early phase after PDT. IL-l is able to induce a 
granulocytosis by the mobilization of neutrophils from their storage pool in the 
bone marrow (18,19). However, the results of the present study show that IL-I 
does not act alone. The administration of anti-G-CSF antibodies revealed that the 
numerical increase of blood neutrophils is at least partially dependent on the 
endogenous production of the granulocyte-specific growth factor G-CSF. This 
growth factor stimulates the proliferation, and maturation of neutrophils in the 
bone marrow, and can also up regulate the activation status of those leukocytes 
(20). It is conceivable that the release of G-CSF is triggered by IL-l ~ upon PDT. 
G-CSF can be produced by many celltypes including fibroblasts and endothelial 
cells after IL-I stimulation both in vitro (21-23) and in vivo (24). In this respect it 
is noteworthy that TNF-a is also capable of inducing G-CSF production as shown 
in vitro by endothelial cells (25) and in vivo (26). Macrophages release TNF-a 
following PDT treatment in vitro (27), but we were not able to demonstrate its 
occurrence in the circulation of the PDT -treated rhabdomyosarcoma rats. 
Activated inflammatory cells make an essential contribution to the anti-tumor 
effect of PDT (3,4,1 I). Although G-CSF at least partially contributes to the 
neutrophilia, administration of anti-G-CSF antibodies has a much greater impact 
on the efficacy of PDT than could be deduced from its effect on the numerical 
course of blood neutrophils after PDT. This suggests that functional activation of 
neutrophils by the granulocyte-selective growth factor G-CSF is of great 
importance for the tumoricidal effect of PDT. It also supports the view that the 
local availability of this and other cytokines is essential to establish granulocyte-T-
lymphocyte cross-talk to overcome the immunosuppressive activity of the tumor 
(13). Neutrophils that can kill tumor cells upon activation by G-CSF (28), may also 
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facilitate the establishment of a specific immune reaction against the tumor. 
Korbelik et al. (5) clearly showed that the activity of host lymphoid populations is 
essential for preventing the recurrence of EMT6 tumors in mice after PDT. In 
accordance with that study we found a sustained decrease of the number of 
lymphocytes in the circulation during the first 24 h after PDT suggesting their 
recruitment to the treated site. 
Taken together, we suppose that the profound neutrophilia upon PDT of 
rhabdomyosarcoma-bearing rats is the result of the action of IL-l. However, IL-l 
most likely did not act alone, but conceivably stimulated the subsequent release of 
the granulocyte-lineage specific growth factor G-CSF. G-CSF on its turn can 
increase the proliferation rate of myeloid precursors in the bone marrow, but more 
importantly elevates the functional activity of neutrophils at the site of the tumor 
lesion. In the absence of G-CSF neutrophils lack to the ability to kill the attenuated 
tumor cells making PDT much less effective. It is obvious that neutrophils are 
crucial for an effective PDT. Contra-indications for PDT should therefore regard 
patients that are treated with severe immunosuppressive (cytostatic) agents unless 
recovered from granulocytopenia (by G-CSF). Future efforts in optimalisation of 
PDT should concentrate on the leukocytes recognized to be important in the 
inflammatory reaction and the cytokines/growth factors important for their 
proliferation and activation. 
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CHAPTER 6 
The effect of thrombocytopenia on the efficacy 
of photofrin-based photodynamic therapy in vivo 
Wi! J.A. de Vree, Hemiette S. de Bruijn, Regina G. Kraak-Slee, 
Johan F. Koster, and Wim Sluiter. 
(Submitted for publication) 
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Abstract 
In the past it was postulated that obstruction of the blood flow is beneficial in 
respect to tumor cure after PDT since tumor cells are deprived of oxygen and 
nutrients under these conditions. On the other hand, a decreased tumor 
oxygenation during PDT may inhibit the generation of toxic oxygen species and 
therefore may impair the direct efficacy of the therapy. Thrombocytes are involved 
in thrombus formation and vasoconstriction observed during and after 
photodynamic therapy (PDT) of tumors resulting in blood flow obstruction. To 
investigate whether preventing this obstruction during PDT will improve the 
efficacy of the therapy, the number of thrombocytes in the blood circulation of 
rhabdomyosarcoma-bearing rats was decreased before the start of PDT by the 
administration of rabbit anti-rat thrombocyte antiserum. This treatment led within 
30 min to a reduction of at least 96% in the number of circulating thrombocytes 
which remained at that level throughout at least 48 h. Growth of tumors treated 
interstitially on the thigh of the animals was significantly retarded under 
thrombocytopenia induced prior to PDT as compared to control PDT conditions at 
a light energy dose of 90 J, suggesting a prominent role for tumor oxygenation in 
the enhanced efficacy. However, treatment of animals with the anti thrombocyte 
antiserum after PDT led to the same increased delay of tumor growth as compared 
to antiserum treatment prior to PDT, thereby outruling this possibility. 
Previously we showed a prominent role for neutrophils in the effectuation of 
the PDT induced damage to the tumor under normal conditions. We therefore 
questioned whether the contribution of these phagocytes to the tumor growth 
retardation could be increased under thrombocytopenia. Upon PDT the amount of 
myeloperoxidase (MPO) activity increased in the tumors of normal and 
thrombocytopenic rats reflecting the accumulation of neutrophils at the site of the 
lesion. In normal rats the tumor MPO content reached a maximum at 24 hr after 
PDT, and rapidly subsided thereafter, while in thrombocytopenic rats the MPO 
accumulation rate was similar, but it did not slow down before 48 hr after PDT and 
then slowly decreased. From the areas-nnder-the-curves it can be estimated that at 
least 1.5 times more neutrophils than normal were present in the PDT-treated 
tumors under thrombocytopenia. Furthermore, when the number of granulocytes 
was decreased by the administration of anti-granulocyte antiserum prior PDT 
followed by anti-thrombocyte antiserum post PDT, this treatment regimen led to a 
considerable loss of the thrombocytopenia-dependent gain in the efficacy of PDT. 
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Apparently neutrophils underlie the observed enhanced efficacy of PDT under 
thrombocytopenia. We hypothesize that in the absence of vasoconstriction and/or 
local clotting either prevented during PDT or abolished after PDT the attenuated 
tumor cells will be better accessible to these activated tumor cell killers. This 
would imply that under normal clinical conditions the full granulocyte-dependent 
kill potential of PDT is not utilised due to the presence of thrombocytes that cause 
blood flow stasis. 
Introduction 
The mechanism underlying tumor eradication after photodynamic therapy 
(PDT) involves direct and indirect events affecting the viability of individual 
tumor cells. Direct cytotoxicity occurs as a result of the generation of highly 
reactive oxygen species such as singlet oxygen (1,2) upon illumination of the 
photosensitizer, which induces oxidation of plasma membranes, mitochondria and 
Iysosomes (3,4). In vivo, not only tumor cells are affected directly by PDT but also 
the endothelial cells lining the blood vessels that provide the tumor with oxygen 
and nutrients. Direct cytotoxicity causes the retraction of the endothelial cells with 
the subsequent exposure of the subendothelial matrix as has been observed in vitro 
(5) and in vivo (6). Neutrophils adhere to the exposed subendothelium (7) and 
thereafter infiltrate the tumor area (8), where the attenuated tumor cells are killed 
directly (9) or via interaction with other leukocytes (10). The importance of this 
non-specific cellular immune reaction to occur is stressed by the fact that several 
immuno-potentiating strategies have successfully enhanced the efficacy of PDT (8, 
10-15). On the other hand, depletion of neutrophils using anti-GRI antibody or 
blocking the [3 chain of integrins by anti-CDl8 antibody decreased the PDT-
mediated tumor cure (13). Furthermore, inhibiting neutrophil action by anti 
granulocyte antiserum almost completely abrogated the effect of PDT on tumor 
growth (16). Cytokines and growth factors are likely to be involved in the immune 
response elicited by PDT as well (17-20). Interleukin 1[3 serum levels for example 
rapidly increase after the start of PDT. This pro-inflammatory cytokine may induce 
the release of granulocyte colony stimulating factor (G-CSF), which in turn can 
stimulate the proliferation and activation of neutrophils, leading to a peak in 
neutrophil numbers in the circulation at 8 h post PDT (20). 
The exposed subendothelium is highly thrombogenic. Indeed next to the 
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adherence of granulocytes, thrombocytes adhere leading to the formation of 
thrombi and to vasoconstriction due to the release of potent vasoactive 
eicosanoids, e.g., thromboxane (21, 22). Eventually these events lead to complete 
stasis of the blood flow. It was postulated that this contributes to indirect tumor 
cell kill due to the deprivation of oxygen and nutrients, because the clonogenicity 
of tumor cells decreased with time after PDT in vivo (23). The necessity of 
vascular shutdown for tumor regression was supported by the fact that 
indomethacine, which inhibits the release of thromboxane by activated 
thrombocytes, decreased the efficacy of PDT (22). However, this could be 
misleading evidence since indomethacine also suppresses the activity of 
neutrophils, which are indispensable for the killing of attenuated tumor cells (16). 
Recently it has been observed that the administration of anti thrombocyte 
antiserum prevents the vasoconstriction and occlusion of the microvasculature 
upon PDT (24). Since this antiserum treatment does not directly affect neutrophil 
function we investigated the effect of thrombocytopenia on the efficacy of PDT 
with special emphasis on the role of neutrophils therein. 
Materials and Methods 
Animals and tumor models 
Female W AG/Rij rats, aged 12-20 weeks, were obtained from Harlan (Zeist, 
The Netherlands). In order to perform interstitial PDT small pieces of a well-
characterized isologous rhabdomyosarcoma, designated as R-l (25) were 
implanted subcutaneously into the thigh. Tumor growth was assessed every day by 
calliper measurements on three orthogonal diameters. Tumors were treated when 
the volume was between 1000 and 1500 mm'. Blood samples were obtained from a 
tail vein with EDTA as the anticoagulant. Total leukocyte and thrombocyte counts 
were determined with a microcell counter, and differential counts were carried out 
on May-Grunwald and Giemsa-stained blood smears. 
Antisera and Photosensitizer 
Adsorbed polyclonal rabbit anti-rat thrombocyte and polyclonal rabbit anti-rat 
granulocyte antisera were purchased from Accurate (Westbury, NY, USA), diluted 
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I to lOin 0.9% NaCI solution and sterilized by 0.2' m filtration before use. 
The photosensitizer Photofrin Il® (PIl) was obtained from Quadra Logic 
Technologies Inc. (Vancouver, BC, Canada) and was reconstituted in 5% glucose 
before use. The photosensitizer was administered i.v. into a tail vein at 10 mg 
PIIIkg 24 hr prior to light delivery. 
Light delivery 
The light source was a dye laser pumped by an Argon ion laser (Spectra 
Physics model 375B and 2040E, respectively). A birefringent filter and 
monochromator were used to tune the dye laser to emit light at 625 ± I nm 
wavelength using DCM (4-dicyanomethylene-2-methyl-6(P-dimethylaminostytyl)-
4H-pyran) as a dye. The light was directed via a beam splitter to three cylindrical 
diffusers of 15 mm length (Rare Earth Medical, Dennis, MA, USA). 
Treatment protocol 
In the first series of experiments, rats were rendered thrombocytopenic by a 
single i.v. injection of 0.5 ml of diluted anti thrombocyte antiserum (containing 
approx. I mg Ig/ml) at 30 min prior or 5 min post PDT. In the next series of 
experiments, rats were rendered neutropenic by a single i.v. injection of 0.2 ml of 
diluted anti granulocyte antiserum at 30 min prior PDT treatment, followed by a 
single injection of 0.5 ml of diluted anti thrombocyte antiserum at 5 min post PDT 
to render the rats thrombocytopenic as well. Thereafter rats were kept neutropenic 
by i.v. injections of 0.1 ml of diluted anti granulocyte antiserum at 2 and 4 days 
after PDT. Control rats were injected with equal volumes of saline. 
Interstitial PDT treatment was performed as previously described (20) with 
minor adaptations. In brief: rats were anaesthetized by i.m. injection of I ml/kg 
Hypnorm (fluanisol/fentanyl mixture; Janssen Pharmaceutica, Beerse, Belgium) 
and Valium. Animals were placed on a heated support during treatment to control 
body temperature. A diffuser was inserted into the central axis of the tumor 
parallel to the body axis. The output of the diffuser was kept below 50 mW per cm 
of diffuser length to avoid hyperthermic effects. Tumor core temperatures were 
measured during PDT using a thermocouple probe and never exceeded 40°C. Total 
applied radiant energy was 90 J (low dose) or 270 J (high dose) per cm of diffuser 
length. Both treatment modalities normally cause delay of tumor growth but not 
tumor regression. 
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Assessment of MPO activity 
As an index of the number of neutrophils the tumor myeloperoxidase (MPO) 
content was assessed. We adapted the biochemical assay described by Grisham et 
al. (26), which was optimized by Graff et al. (27), for tumor tissue to overcome the 
interference of endogenous (enzymic and nonenzymic) reductants by two wash 
steps in the presence of N-ethylmaleimide (NEM) after homogenization, and by the 
addition of hexadecyltrimethylammonium bromide (HTAB) to the assay mixture 
to inhibit the pseudoperoxidase activity of remaining hemoglobin derived from the 
increasing numbers of tumor associated erythrocytes upon PDT. In short, the 
tumor was excised, weighed and homogenized in 3 volumes (v/w) of ice-cold 
modified RIPA buffer (containing 1 % NP40, 0.25% sodiumdeoxycholate, I iJ,g/ml 
aprotinin, leupeptin and pepstatin, and in mM: 50 Tris HCI, 150 NaC!, 1 EDTA, 1 
PMSF, I NaV04, 1 NaF;pH 7.4) using a Polytron homogenizer on setting 5. The 
homogenate was centrifuged at 12,000 g for 30 min at 4°C. The pellet was 
resuspended in ice-cold 50 mM sodium phosphate buffer (pH 7.4) containing 10 
mM NEM, centrifuged again, and if the number of erythrocytes was high, 
resuspended in ammoniumchloride for 20 min at 4°C and centrifuged. The pellet 
was sonicated in 50 mM sodium phosphate buffer (pH 6.0) containing 0.5% 
HTAB (PB-HTAB) by three bursts of 10 sec on setting 20, subjected to three 
cycles of freezing and thawing, and centrifuged (12,000 g, 30 min, 4°C). The MPO 
activity was determined by its ability to catalyze the hydrogen peroxide-dependent 
oxidation of o-dianisidine (o-DA). The reaction was started by the addition of 100-
iJ,1 pre-warmed substrate solution (hydrogen peroxide and o-DA) to 50 !J.l aliquots 
of the serially diluted supernatant in PB mixed with 50 iJ,1 PB-HTAB (final 
concentrations: 3.43 mM HTAB, 0.35 mM hydrogen peroxide, and 0.63 mM 0-
DA). We found that under those conditions optimal reaction rates were attained, 
while the pseudoenzymic activity of hemo- and myoglobin was inhibited by a 
factor of > 100. The change in absorbance at 450 nm was measured during 2 min 
at 37°C in a thermostatted microplatereader (Thermomax, Sopachem, Driebergen, 
The Netherlands). Initial rates of enzyme activity were determined from the linear 
part of the curve, and converted to enzyme units using the molar extinction 
coefficient of of o-DA of 1O,062xM-1xcm-1 (27). We defined one unit of MPO as 
the amount of enzyme that oxidizes o-DA at a rate of I iJ,mol/min under the present 
assay conditions. Under those assay conditions 1 U of bovine MPO (Sigma) 
catalyzes the oxidation of o-DA at a rate of 0.15 iJ,mol/min. In eight experiments, 
the amount of MPO recovered from rat blood neutrophils was 5.70 (± 0.87) xlO-7 
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U MPO/cell, which was nearly equal to the amount of 5.04xlO'7 U reported by 
Bradley et al. (28). Enzymatic MPO activity was routinely confirmed by its 
complete inhibition with 1 mM sodium cyanide or 10 mM sodium azide. 
Statistical analysis 
Data were analysed by unpaired Student's t-test and considered significant when P 
<0.05. 
Results 
Effect of PDT on thrombocyte and lenkocyte numbers after anti-thrombocyte 
antiserum-treatment. 
To study the effect of PDT on the uumerical courses of platelets and leukocytes 
iu the circulation of anti-thrombocyte antiserum-treated rats, blood samples were 
drawn at various time points during the observation period. PDT alone did not 
influence the number of thrombocytes markedly. The administration of antiserum 
prior to PDT, however, led to a 96 % reduction in the number of thrombocytes 
from 687 ± 27 to 26 ± 25 x 109/l within 30 min (not shown). Upon PDT that 
number did not change and remained at that low level throughout at least 48 h (not 
shown). Likewise, if the antiserum was administered directly after PDT the 
number of thromhocytes dropped to almost zero levels after 30 min and did not 
return to the normal level within 48 h. 
The number of circulating leukocytes slowly increased after PDT from 6.9 ± 
3.9 to 14.7 ± 2.6 x IO'/liter. Administration of anti-thrombocyte antiserum prior to 
or post PDT initially led to a maximal decrease of 50-70% of the normal numbers 
within 30 min (not shown). This effect lasted for about 8 h, after which the number 
of leukocytes increased reaching similar elevated levels at 24 h as rats treated with 
PDT only. 
Effect of thrombocytopenia on tumor growth after PDT. 
To investigate whether by preventing blood flow stasis thrombocytopenia 
indeed enhances the efficacy of PDT, rats with rhabdomyosarcoma tumors 
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transplanted on the thigh were used. The normal tumor doubling time (here 
defined as the time needed to reach a doubling in tumor volume as compared to 
day zero) is 3.4 days (Figure 1). 
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Figure 1. Effect of thrombocytopenia on tumor growth after PDT. Tumor volumes of rats 
treated with saline (open circle) or antiserum prior to (open triangle) or post PDT 
(closed triangle) and of untreated rats (closed circle) are expressed as a 
percentage of the tumor volume at the day of treatment. PDT was applied at 90 J 
(Figure I a) and at 270 J (Figure 1 b) per em of diffuser length. Data are the mean 
of six rats. Bars, SD. 
In normal animals PDT treatment at 90 J per cm of diffuser length resulted in a 
prolonged tumor doubling time of 6.26 ± 0.56 days (Figure la). Under 
thrombocytopenia induced prior to illumination, PDT led to a rapid and transient 
increase in tumor volume at one day after treatment which is possibly due to 
oedema formation. A striking feature of the tumors from these rats at that time-
point was the clearly visible extensive and intense necrotic areas (Figure 2a) which 
were not observed in the PDT treated control rats (Figure 2b). Eventually under 
these conditions the tumor doubling time was 7.48 ± 0.84 days, which was 
significantly longer than under the PDT alone condition (P = 0.014). There was no 
difference in growth rates of untreated tumors between normal (Figure 1) and 
thrombocytopenic rats (not shown). 
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Figure 2. Macroscopic appearance of PDT-treated tumors. Shown is a tumor of an 
antiserum (Left) or saline (Right) treated rat 24 h after PDT treatment. 
The length of the thrombocytopenic period induced by the anti thrombocyte 
antiserum prior to PDT is not restricted to the phase of light treatment, which 
makes it impossible to attribute the beneficial effect of this accessory treatment 
only to an improved supply of oxygen during PDT. We therefore decided to study 
the effect of thrombocytopenia induced after PDT. Strikingly the administration of 
the antiserum post PDT led to a comparably longer tumor doubling time (7.56 ± 
1.25 days) as in the rats treated with antiserum prior the PDT treatment which was 
statistically different from PDT only rats (P = 0.043; Figure la). At the higher light 
energy dose of 270 J per cm of diffuser length PDT only led to an estimated tumor 
doubling time of 9.65 ± 2.19 days, which is significantly longer than at 90 J cm (P 
= 0.004; Figure la and 1 b). Strikingly, tumors treated with this high energy light 
dose in combination with the antiserum treatment post PDT on average did not 
resume to grow at all within the observation period (Figure lb). 
The involvement of neutrophils in the enhanced efficacy of PDT under 
thrombocytopenia. 
Since there was no difference in tumor response to PDT in rats treated with 
anti-thrombocyte antiserum prior versus post PDT it is unlikely that under 
thrombocytopenic conditions an improved supply of oxygen underlies the 
observed enhanced efficacy of PDT. Other mechanisms may therefore account for 
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this phenomenon. In a previous study we showed evidence for an impOltant role 
for neutrophils in the effectuation of the PDT induced damage (16). We therefore 
questioned whether the activity of these phagocytes underlies the observed 
enhanced PDT effect under thrombocytopenia as well. In order to investigate this, 
tumors from each treatment group were excised at several time-points after PDT 
(270 J/cm) and assayed for MPO content, which is an indicator for the presence of 
neutrophils (Figure 3). 
Figure 3. Effect of treatment on tumor MPO content. Shown is the activity of MPO per g 
tumor wet wt after treatment by PDT at 270 J/cm only (open circle), and in 
combination with the administration of anti thrombocyte antiserum post PDT 
(closed circle). Data are the mean of two to three rats. Bars, SD. 
As shown the activity of MPO in the tumor of normal rats rapidly increased upon 
PDT to a maximum of 0.34 (± 0.06) U MPO/g tumor (eqUivalent to 6.04 x 105 
neutrophils) at 24 hr and declined thereafter to 50% within the next 24 hr. 
However, under thrombocytopenia the increase in MPO activity did not diminish 
earlier than after 48 hr (maximum: 0.37 ± 0.0 I U MPO/g tumor, equivalent to 6.56 
x 105 neutrophils) , and only slowly subsided thereafter. From the areas-under-the-
curves it can be estimated that about a factor of 1.5 more neutrophils than normal 
accumulated into the PDT -treated tumors under thrombocytopenia. However, the 
increase in the accumulation of neutrophils at the tumor lesion under 
thrombocytopenia does not necessarily prove their contribution to the enhanced 
efficacy of PDT. In order to investigate this, anti-granulocyte antiserum was 
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administered prior to PDT followed by anti-thrombocyte and anti-granulocyte 
antiserum post PDT. This treatment regimen led to a significantly lesser effect of 
PDT on tumor growth as compared to thrombocytopenia only (tumor doubling 
time of 5.44 ± 1.38 days, P = 0.021; Figure 4). 
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Figure 4. Effect of anti-granulocyte antiserum on the thrombocytopenia induced enhance-
ment of PDT efficacy. Shown are the tumor volumes of rats pretreated with anti-
granulocyte antiserum prior PDT, followed by treatment with anti-thrombocyte 
and anti-granulocyte antiserum post PDT (closed square), For comparison, the 
tumor volumes of rats treated with saline (open circle) or anti-thrombocyte 
antiserum post PDT (closed triangle) and of untreated rats (closed circle; data of 
Figure 1) are shown. Data are the mean of six rats. Bars, SD. 
Discussion 
This study shows that the efficacy of PDT is affected by thrombocytes, which 
are involved in vascular events occurring as a result of treatment. Recently it was 
shown that depletion of circulating thrombocytes by use of anti thrombocyte 
antiserum administered prior to PDT led to an inhibition of vascular constriction 
and occlusion by thrombi (24). In the present study we demonstrated that under 
these conditions the damage inflicted upon tumors by PDT is enhanced. This was 
expected since previous studies showed that PDT induced damage is dependent on 
the generation of singlet oxygen (1,2). Under thrombocytopenia Fingar et al. (24) 
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showed that the blood flow and thus the supply of oxygen, is uninterrupted during 
PDT due to the absence of vascular events that may lead to an enhanced generation 
of singlet oxygen. Surprisingly however we found exactly the same enhancing 
effect of PDT on tumors when the antiserum was administered after the end of 
treatment. Obviously, the latter condition did not allow for an improved generation 
of singlet oxygen. Apparently, another mechanism underlies the observed 
enhanced efficacy. Presently, we can only speculate at this point. In 
thrombocytopenic animals the number of neutrophils that accumulated in the PDT-
treated tumor area was increased. Furthermore, the enhanced efficacy of PDT on 
tumors could be abrogated by pre-treatment of animals with anti-granulocyte 
antiserum. We therefore conclude that the enhanced killing of tumor cells is 
caused by an increase in the number of tumor-associated neutrophils under 
thrombocytopenia. Henderson et al. have found that the clonogenicity of tumor 
cells deteriorates with time after PDT, despite the fact that during PIT-based PDT 
blood vessels occlude, thereby hampering the direct tumor cell kill (23). It was 
postulated that this secondary killing effect of PDT was due to the deprivation of 
oxygen and nutrients as a result of the blood flow stasis. The result of the present 
study indicate that another factor, i.e., the activity of tumor-associated 
granulocytes, has to be taken into account as well. These phagocytes need time to 
accumulate into the area of photodamage of the tumor. Fingar et al. (7) showed 
that upon PDT granulocytes adhere to the blood vessel wall within 5 min. 
However thereafter, a time consuming process of diapedesis of the subendothelial 
matrix, migration to the attenuated tumor cells and their destruction will follow. If 
indeed these granulocytes playa major role in the efficacy of PDT, the blood flow 
stasis will not promote, but inhibit the secondary PDT-dependent tumor cell kill by 
hindering their entry into the lesion. We found evidence that under 
thrombocytopenia induced after PDT the blood vessels apparently reopen 
facilitating the accumulation of neutrophils into the damaged tumor, because 
between 16 and 48 hr later the hemoglobin content of the tumors in 
thrombocytopenic rats was a factor of 3-4 times higher than in PDT-treated normal 
rats (not shown). This hypothesis is supported by the evidence found by others 
(29,30) that inhibition of nitric oxide (NO) synthase or scavenging NO may 
increase the efficacy of PDT through relieving the NO mediated suppression of the 
extravasation and tumoricidal activity of neutrophils. Indeed, NO can inhibit the 
adherence of neutrophils to the blood vessel wall (31) and inactivate the 
superoxide anion radical produced by activated granulocytes (32). 
In conclusion, we found that under thrombocytopenic conditions, the efficacy 
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of PIT-based PDT of the rhabdomyosarcoma R-J increased. It seems likely that an 
increased accumulation of neutrophils in the PDT-treated tumor underlies this 
phenomenon. 
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CHAPTER 7 
General discussion 
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General discussion 
The research described in this thesis was aimed at improving the efficacy of 
PDT. The vast majority of studies on PDT report about improving "conditional" 
aspects; i.e. the development of photosensitizers with absorption maxima at longer 
wavelengths, improved illumination techniques and protocols, the use of diverse 
routes of administration and vehicle of the sensitizer and so on. These are all 
important factors determining the primary tumor cell kill mediated by singlet 
oxygen. However, primary cell kill may not be sufficient for total tumor control. 
Secondary cell killing mechanisms are needed for complete cures as well. 
Therefore, a total understanding of the "basics" on how PDT works is essential. 
The results of our studies described in the previous chapters show the 
indispensable contribution of activated neutrophils for successful PDT. We found 
that the number of neutrophils in the circulation and in the tumor lesion increased 
upon PDT (Chapter 5,6). Definitive proof however was the finding that their 
depletion led to a considerable reduction in the treatment success rate (Chapter 4). 
An open question remains how these phagocytes improve the effect of PDT. 
Despite that, it is likely that this role of neutrophils in establishing the (long-term) 
treatment success is not restricted to PIT-based PDT in rat rhabdomyosarcomas, but 
can also be valid for PII or other sensitizers in other experimental (tumor) models 
as well. For example, in murine squamous cell carcinoma tumors (I) or in EMT6 
tumors (2) a rapid and massive accumulation of neutrophils after the start of PII-
based PDT was found. Similar results were obtained when meta-
TetraHydroxyPhenylChlorin (mTHPC) was used as a photosensitizer in the EMT6 
tumor model (3). Also the illumination of mTHPC in normal trachea of pigs led to 
an intense inflammatory reaction with edema and infiltrating PMN cells (4). 
Moreover, one day after mTHPC-based interstitial PDT of the peritoneum of rats a 
shift in the differential counts of peripheralleucocytes from lymphocytes towards 
predominantly granulocytes was found (5). Clearly, these observations are 
circumstantial, but recently our conclusion about the role of neutrophils in the 
secondary effect of PDT has been confirmed in a murine tumor model. The anti-
GR I antibody which depleted neutrophils diminished the PDT induced cure rate in 
tumor-bearing mice (6). However, using the anti-CD 18 antibody which blocks the 
function of the ~ integrin chain of neutrophils the outcome was dependent on the 
tumor type. While the curative effect of PDT on the EMT6 tumor was completely 
abolished, surprisingly, the effect on the SCCVII tumor was markedly potentiated 
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(7). This latter result may indicate that other cell types than neutrophils are 
involved in the resistance to this squamous cell carcinoma. 
The finding that granulocytes play an important role in the PDT induced 
damage to tumor cells (chapter 4) was very surprising. The general concept is that 
immune responses directed to the tumor normally consist of mainly tumor-
infiltrating (cytotoxic) lymphocytes or macrophages rather than granulocytes. 
Evidence exists that (T)-lymphocytes indeed are important in the subsequent tumor 
control upon PDT. This evidence is based on the curative effect on PDT treated 
tumors of adoptively transferred bone marrow (8) or spleen cells (9) from mice 
cured by PDT to immunodeficient scid mice with a syngeneic tumor. More 
recently the use of specific antibodies against the T-cytotoxic lymphocyte 
determinant CD8 intervened with an effective PDT response (10). It seems not 
very likely that T-Iymphocytes are involved in direct tumor cell kill since the 
notion that breast cancer and Karposi sarcoma patients with acquired 
immunodeficiency syndrome (AIDS) responded well to tin etiopurpurin-based 
PDT in terms of tumor cure (II). This is confirmed in an experimental mouse 
tumor model using anti-CD8 antibodies in vivo and in vitro to deplete these 
lymphocytes prior to adoptive immunotherapy in immunodeficient hosts to be 
treated with PDT (12, 6). Also if lymphocytes were depleted by anti lymphocyte 
antiserum prior to PDT in the rat rhabdomyosarcoma model, tumor growth 
retardation was not decreased, but was comparable to PDT treated control animals 
(de Vree, unpublished results). It is more likely that lymphocytes playa role in the 
generation of a specific tumor response after PDT. This may occur if direct 
damage to tumor cells leads to a massive accumulation of neutrophils. The 
occurrence of such a strong local inflammatory response may be regarded as 
characteristic for PDT enabling the immune system to mount an effective response 
to the tumor. In that respect PDT differs from radiation therapy for instance, which 
induces more apoptosis than necrosis of the tumor cells (12). Neutrophils attracted 
to the lesion site after PDT may degrade tumor cells that have escaped primary cell 
kill and attract lymphocytes by the release of chemotactic factors and cytokines. 
The cellular debris is then taken up by for example resident macrophages which 
are activated by photodynamically killed tumor cells (13). These macrophages can 
process this debris and function as antigen presenting cells (APC). Upon the 
presentation of these processed tumor cell antigens in the context of the proper 
MHC molecules, T-cells are activated and clonal expansion of T-cells recognizing 
tumor antigens leads to a specific memory immune response that will maintain 
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long-term resistance to rechallenge with the same tumor (12). Next to their role of 
non-specific effector cells evidence exists that granulocytes can act as APe 
themselves and thus may participate in the generation of a specific memory 
immune response as well (14). Whether this is the case in PDT induced specific 
immunity remains to be established. 
PDT based on various types of photosensitizer often leads to vascular stasis and 
damage. This may seem an unwanted side-effect, because it limits the generation 
of toxic singlet oxygen. The general concept, however, is that this negative effect 
is fully compensated by the fact that the tumor cells will subsequently die as a 
consequence of the lack of oxgen. Experimental evidence for this is based upon the 
deterioration in clonogenicity of PDT treated tumor cells in time (15) and on the 
inhibitive effects on tumor cure of NSAID's that prevent vessel constriction (16-
19). However these latter agents also affect granulocyte function (20). Therefore, 
the hypothesis that vascular damage due to blood flow stasis is essential to PlI-
based PDT at least needs shading. For preventing vascular stasis may also lead to 
increased tumor damage because it facilitates the accessibility of activated 
neutrophils to the tumor (chapter 6). We used a relative low light fluency for PDT. 
It could be reasoned that increasing the fluency would increase the direct tumor 
cell kill by PDT putting in perspective the necessity of the performance of the 
neutrophils. However, Veenhuizen & Stewart in attempt to classify the available 
literature on fluency rate effects in PDT came to the conclusion that the optimal 
fluence rate for PDT-induced tumor damage lies between 50 en 100 mW.cm·2 (21). 
Furthermore, there are several recent studies in which low fluence rates or 
intermittence of illumination over several periods of time instead of one 
continuous period resulted in better tumor responses (22-27). This may be due to a 
renewed influx of oxygen so that more singlet oxygen can be generated. Although 
these approaches increase the direct effect of PDT and concomitantly the need for 
accessory mechanisms may decrease, the recent work of Korbelik et al. shows that 
even after a complete response of the tumor to PDT the presence of neutrophils 
cannot be missed to prevent remission (6). 
To date Photofrin is the only sensitizer approved for clinical settings. In 
contrast to what is generally accepted we have shown here that vascular 
constriction may not be necessary per se for efficient PDT. Therefore, it remains to 
be established if second- and third-generation photosensitizers with less 
pronounced effects on the vasculature will indeed achieve better tumor responses 
than PlI. 
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Taken together, the data presented in this thesis suggest the following sequence 
of events during and shortly after PDT (Figure 1). 
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Figure 1. Proposed mechanism of tumor cell kill by PDT on the bases of the presented data 
in chapter 2 to 6. 
PDT kills many tumor cells directly by the generation of singlet oxygen or 
other toxic molecules (directly killed tumor cells are represented by open circles 
with cross in Figure 1). At a certain distance from the capillaries the limited supply 
of oxygen diminishes the generation of singlet oxygen. As a result some tumor 
cells escape direct killing, and may become attenuated only (discontinuous circles) 
while other cells may even survive the treatment (open circles without cross). PDT 
not only kills the tumor cells but also affects the endothelial cells lining the wall of 
the tumor blood vessels. These latter cells contract upon PDT which results in the 
exposure of the subendothelial matrix. PDT did not increase the expression of 
cellular adhesion molecules on the endothelium and did not alter the production of 
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NO, prostacyclin or vWF of this tissue. Granulocytes (open circles with crinkle) 
adhere directly to the subendothelial matrix and then migrate to the lesion site 
attracted by the large amounts of debris released from killed tumor cells. Upon 
phagocytosis of this material nentrophils and resident macrophages produce pro-
inflammatory cytokines like IL-I, IL-6 or TNF-a. IL-I~, which is demonstrable in 
the circulation after PDT, is capable of stimulating the subsequent production of 
G-CSF by endothelial cells and fibroblasts. G-CSF not only stimulates the 
production of neutrophils in the bone marrow, but activates neutrophils already 
present in the circulation as well. On their way to the lesion site, these activated 
neutrophils are hindered by thrombocytes adhering to the subendothelial matrix of 
the vessel wall and by stasis of the blood flow. However, once these neutrophils 
arrive into the tumor it is conceivable that large amounts of lysosomal proteinases 
and superoxide anions will be produced which kill the attenuated tumor cells. 
Furthermore, by their presentation of tumor antigens and the production of 
cytokines these phagocytes will enhance the specific immune response to the 
tumor preventing its regrowth. 
Although the findings presented in this thesis are promising for increasing the 
efficacy of PDT, the use of G-CSF (and other growth factors) must be put into 
perspective. A recent report indicates that G-CSF can increase the invasive 
potential of a number of head-and-neck-carcinoma cell lines which express the G-
CSF receptor (28). Moreover, Ferrario & Gomer (29) showed that PDT in the 
range of light doses required to obtain tumor cures induced a high level of acute 
lethality in mice consistent with a traumatic shock syndrome. Therefore further 
research is warranted before such an adjuvant therapy directed at increasing the 
number and activation status of neutrophils in the tumor can be safely applied in 
PDT -treated patients. 
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Summary 
The study described in this thesis was aimed at elucidating the mechanisms 
underlying the interaction between endothelial cells and granulocytes and at 
investigating the relevance of this interaction for the effect of PDT. First it was 
observed that granulocytes rapidly adhere to the vessel wall upon PDT. The 
mechanism underlying this adherednce was investigated in an in vitro model 
comprised of monocellular layers of human vascular endothelium and human 
granulocytes. In this model it was shown that granulocytes rapidly adhered after 
PDT dependent on sensitizer and light dose and on the time point of addition of 
granulocytes. Cellular adhesion molecules on the endothelial cells were not likely 
to playa role in the adhesion since their expression was not augmented by PDT. 
Also the adhesion of granulocytes could not be blocked by inhibitive antibodies to 
these molecules. In a related study it was shown that the increased neutrophil 
adherence was not dependent on a supposed decreased release of the anti-adhesive 
factors NO and prostacyclin by the PDT-treated endothelial cells. Antibodies 
directed to ~2-integrin adhesion receptors on granulocytes however blocked their 
adhesion substantially, showing the involvement of this ligand. Accurate 
macroscopic analysis of endothelial cells treated by PDT revealed a gradual 
contraction of the endothelium which coincided with the increased adhesion of 
granulocytes. Granulocytes only adhered to culture wells occupied by endothelial 
cells pointing at the involvement of the subendothelial matrix produced by these 
cells. At 4°C or by preincubation of the neutrophils with staurosporin their adherence 
to the subendothelial matrix exposed by PDT of endothelial cells could be prevented. 
Apparently, activation of the ~2-integrin receptor by interaction with the 
subendothelial matrix is necessary for the increased binding of neutrophils. These in 
vitro findings suggest that the PDT -induced contraction of the endothelial cells 
pennits neutrophil adherence to the subendothelial matrix. It is conceivable that a 
similar mechanism contributes to the initial adherence of granulocytes to the vessel 
wall as observed after PDT in vivo. 
Next we questioned whether the observation of adhering granulocytes was of 
relevance for the efficacy of PDT in vivo. This was studied in rhabdomyosarcoma-
bearing rats in which the number of these phagocytes was decreased or increased 
before interstitial PDT by use of anti-rat neutrophil serum or G-CSF, respectively. 
The antiserum led to a complete depletion of circulating neutrophils. Under these 
conditions PDT did not retard tumor growth at all. However, after cessation of the 
99 
antiserum treatment 5 days after PDT a striking decrease in growth rate occurred 
subsequent to an increase above the normal range of the number of circulating 
neutrophils. Administration of G-CSF on the other hand led to a specific increase 
in the numbers of circulating neutrophils. In these animals the tumor growth at day 
two after PDT was retarded as compared with PDT treated animals that received 
saline only. By statistical analyses of both experimental conditions it was shown 
that the efficacy of PDT was dependent on the number of circulating neutrophils 
present at the day of PDT. It is therefore concluded that neutrophils are 
indispensable for succesfull PDT in vivo. 
Several investigators have observed a rapid accumulation of these neutrophils 
into the tumor lesion. In order to clarify the mechanism underlying this increased 
accumulation, we determined the effect of PDT on the course of mature and 
immature neutrophils in the circulation of rhabdomyosarcoma-bearing rats, and 
studied the changes in the level of ILl~ as an important stimulator of the 
proliferation of precursor cells of granulocytes in the bone marrow. It was shown 
that the effect of PDT on tumor growth was preceded by a rapid and specific 
increase of the number of mature neutrophils in the peripheral blood reaching 
maximum values after 8 h. This increment was preceded by an increase of band 
neutrophil numbers and elevated serum levels of IL-l~ being maximal at 2 h after 
the start of PDT. Further investigation showed that injection of anti G-CSF 
antibodies not only attenuated the increase in neutrophil numbers, but also 
decreased the efficacy of PDT. On this basis it is supposed that an IL-I-induced 
release of G-CSF by PDT underlies the nonspecific immune reaction to the tumor. 
Apparently, G-CSF not only stimulates the production rate of neutrophils in the 
bone marrow, but also increases their functional activity to become the 
indispensable tumor cell killers. 
Next to neutrophils also thrombocytes can adhere to the exposed subcellular 
matrix causing blood flow obstruction after PDT. To investigate whether 
preventing this obstruction during PDT will improve the efficacy of the therapy, 
the number of thrombocytes in rhabdomyosarcoma-bearing rats was decreased 
before the start of PDT by the administration anti-rat thrombocyte antiserum. This 
treatment led to a depletion of thrombocytes and subsequent tumor growth 
retardation as compared to control animals. However treatment of animals with 
antiserum after PDT led to the same increased delay of tumor growth, thereby 
ruling out the possibility that enhanced production of singlet oxygen underlied the 
increased efficacy of PDT. Since we found that the myelopeoxidase content of the 
tumors upon PDT was increased under thrombocytopenia to a much higher level as 
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compared to normal rats, we then questioned whether the increased contribution of 
neutrophils to tumor growth retardation could be the underlying mechanism. To 
answer this the number of granulocytes was decreased by the administration of 
anti-granulocyte antiserum prior PDT followed by anti-thrombocyte antiserum post 
PDT. This treatment regimen led to a considerable loss of the thrombocytopenia-
dependent gain in the efficacy of PDT. Apparently neutrophils underlie the 
observed enhanced efficacy of PDT under thrombocytopenia as well. It is 
hypothesized that in the absence of blood flow obstruction the attenuated tumor 
cells will be better accessible to these activated tumor cell killers. This would 
imply that under normal clinical conditions the full granulocyte-dependent killing 
potential of PDT is not utilised due to the presence of thrombocytes. 
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Samenvatting 
Het onderzoek beschreven in dit proefschrift behelsde de interactie tussen 
endothee! cellen en granulocyten en het belang van deze interactie voor het effect 
van PDT . Er is waargenomen dat granulocyten snel aan de vaatwand kunnen 
hechten als gevolg van PDT. Het mechanisme dat ten grondslag ligt aan deze 
adhesie werd bestudeerd aan de hand van een in vitro model bestaande uit een 
monolaag van humaan vasculair endotheel cellen en humane granulocyten. Ook in 
dit in vitro model is aangetoond dat granulocyten sne! hechten na PDT. De mate 
van hechting was afhankelijk van de gebruikte hoeveelheid fotosensitizer en licht 
en het tijdstip waarop granulocyten werden toegevoegd. Cellulaire adhesie 
moleculen op de endotheel cellen speelden waarschijnlijk geen rol in deze adhesie 
omdat hun expressie niet verhoogd was door PDT. Ook kon de hechting van 
granulocyten niet worden geremd met blokkerende antilichamen gericht tegen deze 
adhesie moleculen. In een gerelateerde studie werd aangetoond dat de verhoogde 
aanhechting van neutrofielen ook niet afhankelijk was van een veronderstelde 
verlaging van de anti-adhesie factoren NO en prostacycline door de PDT-
behandelde endotheel cellen. Antilichamen gericht tegen de ~z-integrine adhesie 
receptoren op granulocyten blokkeerden hun adhesie echter grotendeels wei, wat de 
betrokkenheid van dit ligand bij de hechting aantoont. Nauwkeurige macroscopische 
analyse van PDT -behandelde endotheel cellen onthulde een graduele contractie van 
het endotheel welke samenviel met een toenemende adhesie van granulocyten. 
Granulocyten hechtten aileen aan kweek platen waarop endotheel cellen hebben 
gezeten. Dit wijst op de betrokkenheid bij de hechting van de subendotheliale matrix 
geproduceerd door deze cellen. Bij 4°C of door pre-incubatie van neutrofielen met 
staurosporine kon hun adhesie aan de subendotheliale matrix, die dus vrijkomt na 
PDT behandeling van het endotheel, worden voorkomen. Blijkbaar is activatie van 
de ~2-integrine receptor door interactie met de subendotheliale matrix nodig voor 
een verhoogde hechting van neutrofielen. Deze in vitro bevindingen suggereren dat 
de, door PDT -getnduceerde, contractie van het endotheel neutrofiel adhesie aan de 
subendotheliale matrix mogelijk maakt. Het is zeer wei voorstelbaar dat een 
vergelijkbaar mechanisme bijdraagt aan de initieIe adhesie van granulocyten aan 
de vaatwand zoals geobserveerd na in vivo PDT. 
Vervolgens vroegen we ons af of de observatie van adhererende granulocyten 
wei van belang was voor de efficientie van PDT in vivo. Dit werd bestudeerd in 
ratten getransplanteerd met rhabdomyosarcoma tumoren. Het aantal van deze 
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fagocyten werd verlaagd of verhoogd v66r interstitiele PDT met behulp van 
respectievelijk anti-rat neutrofiel antiserum of G-CSF. De injectie van het 
antiserum had een complete depletie van circulerende neutrofielen tot gevolg. 
Onder deze omstandigheden werd de groei van de tumor na PDT behandeling 
helemaal niet geremd. Echter, toen de antiserum behandeling 5 dagen na PDT 
werd stopgezet trad een onverwachte verlaging van de groeisnelheid van de 
tumoren op, tegelijk met een toename van het aantal circulerende neutrofielen tot 
boven het normale niveau. Injectie van G-CSF vlak vaar interstitiele PDT 
veroorzaakte een snelle specifieke toename van het aantal circulerende 
neutrofielen. In deze dieren was de tumor groei 2 dagen na PDT vertraagd in 
vergelUking met ratten die aIleen fysiologisch zout ontvingen. Na statistische 
analyse van beide experimenten bleek dat de efficientie van PDT afhankelijk was 
van het aantal circulerende neutrofielen dat aanwezig was op de dag van PDT 
behandeling. Oaarom mag worden geconcludeerd dat neutrofielen onmisbaar zijn 
voor een succesvolle PDT in vivo. 
Verscheidene onderzoekers hebben een snelle ophoping van deze neutrofielen 
waargenomen in de tumor laesie na PDT. Om het mechanisme dat ten grondslag 
ligt aan deze ophoping op te helderen bepaalden we het effect van PDT op het 
aantal volgroeide en onvolgroeide neutrofielen in de circulatie van ratten met 
rhabdomyosarcomas. Bovendien zijn de veranderingen in het serum niveau van 
IL I ~ -een belangrijke stimulator voor de proliferatie van voorloper cellen van 
granulocyten in het beenmerg- bestudeerd. Het bleek dat het effect van PDT op de 
tumor groei vooraf werd gegaan door een snelle en specifieke toename van het 
aantal volgroeide neutrofielen in het perifere bloed met maximale waarden 8 uur 
na PDT. Oeze toename werd vooraf gegaan door een toename van het aantal 
staafkernige (onvolgroeide) neutrofielen en een verhoogd serum niveau van IL-I ~ 
met een maximum op 2 uur na de start van PDT. Nader onderzoek toonde aan dat na 
injectie van anti G-CSF antilichamen niet aIleen de toename van het aantal 
neutrofielen verminderde maar dat ook de efficientie van PDT verslechterde. Om 
deze reden veronderstellen wij dat een IL-I gelnduceerde productie van G-CSF door 
PDT de non-specifieke immuun reactie tegen de tumor tot gevolg heeft. Blijkbaar 
stimuleert G-CSF niet aIleen de productie van neutrofielen in het beenmerg maar ook 
hun functionele activiteit met als gevolg dat ze tumor eel killers worden. 
Naast neutrofielen kunnen ook thrombocyten hechten aan de geexposeerde sub-
cellulaire matrix. Oit kan na PDT gepaard gaan met een (tijdelijke) obstructie van 
de bloedstroom en daarmee mogelijk met een minder efficiente therapie. Om te 
bestuderen of het voorkomen van deze obstructie tijdens PDT de efficientie van de 
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therapie zal verbeteren, werd het aantal thrombocyten In ratten met 
rhabdomyosarcomas verlaagd voor de start van PDT door injectie van anti-rat 
thrombocyten antiserum. Deze behandeling leidde, zoals verwacht, tot een depletie 
van thrombocyten en had een vertraagde tumor groei in vergelijking met controle 
dieren tot gevolg. Echter, behandeling van dieren met antiserum na PDT leidde tot 
dezelfde mate van vertraging van tumor groei, hetgeen de mogelijkheid dat een 
verhoogde productie van singlet oxygen de verhoogde efficientie van PDT 
veroorzaakt uitsluit. Omdat we vonden dat het myeloperoxidase gehalte van 
tumoren na PDT onder thrombocytopenie was verhoogd tot een veel hoger ni veau 
dan bij normale ratten, vroegen we ons af of een verhoogde bijdrage van 
neutrofielen aan de tumor groei vertraging ten grondslag lag. Om deze vraag te 
beantwoorden werd het aantal granulocyten verlaagd door toevoeging van anti-
granulocyten antiserum voor PDT gevolgd door het anti-thrombocyten antiserum 
na PDT. Deze behandeling leidde tot een aanzienlijke daling van de onder 
thrombocytopenie verkregen winst in de efficientie van PDT. Blijkbaar zijn 
neutrofielen dus ook verantwoordelijk voor de onder thrombocytopenie verkregen 
verhoogde efficientie van PDT. Onze hypothese luidt dan ook dat in de 
afwezigheid van obstructie van de bloedstroom de verzwakte tumor cellen beter 
bereikbaar zijn voor deze geactiveerde tumor cel killers. Dit zou impliceren dat 
onder normale klinische condities het volledige grannlocyt-afhankelijke kill 
potentieel van PDT niet gebruikt wordt door de hinderlijke aanwezigheid van 
thrombocyten. 
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